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1.  Introduction 
1.1  Hemostasis 
Hemostasis is an essential feature of the human defense system and the physiological 
response to blood vessel damage and injury of endothelial cells. Initially, the blood flow 
is reduced by local vasoconstriction, accompanied with aggregation of activated 
platelets to instantly cover the lesion of the endothelium and consequently prevent 
further extravasation of the blood. This initial process is also referred to as primary 
hemostasis. The concurrent activation of the coagulation proteases induces extensive 
fibrin generation, finally resulting in a stable fibrin-clot, which seals the surface of the 
blood vessel. Correspondingly, this process is described as secondary hemostasis.      
Importantly, this hemostatic response is strictly limited to the site of vessel injury, 
physiologically not affecting the systemic blood flow. Thus, an accurate, locally limited 
interaction of thrombocytes and damaged endothelium as well as a precise regulation 
of procoagulant and anticoagulant mediators is required. In the case of a pathological 
predominance of either condition, thrombotic formation or bleeding disorder, 
respectively, will result. 
 
1.1.1 The pathways of coagulation 
The classic model of the coagulation system distinguishes two different pathways of 
coagulation, the extrinsic and the intrinsic pathway, each characterized by a cascade of 
reactions of proteases and cofactors. Primordially, both coagulation pathways were 
thought to independently contribute to fibrin formation during hemostasis. However, 
presently a more complex scheme of coagulation emerges and research up to date 
indicates a preponderant importance of the extrinsic pathway as the main activator of 
coagulation in vivo (1-4). The intrinsic pathway, also referred to as contact activation 
pathway, is initiated by surface contact (5-7) and includes the Hageman factor (FXII), 
factor XI (FXI), kallikrein (KLK) and high molecular weight kininogen (HK). While its 
contribution to fibrin formation in hemostasis is presumed to be of minor importance, 
the contact activation factors were found to be involved in pathological thrombosis and 
in other activities related to modulation of the complement- and kinin-system. 
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1.1.2  Contact activation pathway 
1.1.2.1 Factor XII  
The gene encoding for FXII is located on chromosome 5 (8). FXII zymogen is 
synthesized in the liver (9) and secreted as a single chain glycoprotein with a molecular 
weight of 80kDa (10). In vitro FXII has been found to have the special property of 
autoactivation when bound to activating surfaces. Activation of FXII can either result in 
generation of activated α-FXII (α-FXIIa) or by further cleavages in formation of 
activated β-FXII (β-FXIIa), also referred to as Hageman fragment (HFf), both 
possessing serine protease activity (11). Activated α-FXII consists of an amino-terminal 
heavy chain of 50 kDa and a carboxyl terminal light chain of 28 kDa, linked by a 
disulfide bond (12, 13). β-FXIIa is also composed of two chains, the 28 kDa chain 
identical with the light chain of α-FXIIa and a 2 kDa chain, which originates from the 
heavy chain, equally held together by a disulfide bond (11, 12, 14).    
 
 
Figure 1.1 Contact activation pathway.                
FXII is converted when bound to negatively charged surface into activated FXII (FXIIa). FXIIa activates 
prekallikrein (PK) into kallikrein (KLK), which reciprocally activates FXII. Additionally KLK cleaves high 
molecular weigh kininogen (HK) into HKa under release of vasoactive and proinflammatory bradykinin 
(BK). HK has an accelerating impact on KLK triggered FXII activation. FXIIa further activates FXI, FXIa 
cleaves FIX, a protease known to essentially contribute to coagulation.   
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1.1.2.1.1 FXII structure 
Structurally, FXII is composed of various functional domains. Starting at the amino-
terminus following regions were immuno-localized: The fibronectin domain type II, 
followed by an epidermal growth factor (EGF)-like domain, a fibronectin domain type I, 
a second EGF-like domain, a kringle-domain, a proline-rich domain and a carboxy-
terminal located catalytic domain (14). Although the different domains of FXII have 
been identified, not all functional properties of the respective regions are yet 
determined. Surface binding sites have been detected in the fibronectin domain type II 
(residues 1-28) (15) and type I region (residues 134-153) (16). An additional surface 
binding site is surmised in either the kringle domain or the second EGF-like domain 
(10). The first EGF-like as well as the fibronectin type II region were identified to 
contain binding sequences for zinc, a putative promoter of FXII surface binding and 
activation (17, 18).  Previous studies further provided evidence of a critical role of the 
fibronectin type II domain (residues 3-19) in FXI activation and interaction with 
endothelial cells and neutrophils (19-21). The precise function of the EGF-like domains 
of FXII remains to be examined; however, a mitogenic effect of this region has been 
demonstrated (22). Containing the catalytic domain, the light chain represents the site 
of proteolytical activity. This section includes the catalytic triad, composed of the amino 
acid residues His393-Asp442-Ser544, which is specific for serine proteases and essential 
for its enzymatic activity (23). The amino acid sequence of the catalytic domain has 
been found to share homologies with those of other proteases, notably plasmin, tissue 
plasminogen activator (t-PA) and urokinase (12). The proline-rich domain, however, 
appears to be unique for FXII, its significance is not yet understood. It is worthwhile 
noting that the structure of FXII has a particularly striking similarity with the t-PA, only 
differing in one domain; whereas FXII consists of the proline-rich domain, t-PA contains 
a second kringle region (14).   
 
 Figure 1.2 Model of FXII structure with detail view on catalytic domain.  
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1.1.2.1.2 FXII activities 
Containing both the catalytic domain, α-FXIIa and β-FXIIa possess the ability of 
proteolytically activating prekallikrein (PK) to kallikrein (KLK), which launches the kinin-
kallikrein system and reciprocally activates FXII, a reaction found to be enhanced by 
the cofactor high molecular weight kininogen (HK) (13, 24). Furthermore β-FXIIa 
possesses the property of promoting immunological defense by activating the first 
component (C1) of the classical complement pathway (25-27). However, lacking the 
particular domains, β-FXIIa does not bind to negatively charged surfaces (26). Also the 
ability to initiate the clotting activity of the intrinsic pathway by proteolytical activation of 
coagulation FXI is exclusively reserved to α-FXIIa (27).                 
Besides its procoagulant activity, in purified systems FXII has also been demonstrated 
to contain fibrinolytic properties at physiological concentration by direct activation of 
plasminogen (28, 29). This property has been reported to be enhanced by negatively 
charged surfaces, dextran sulfate (30) and in the presence of zinc ions (29). 
Furthermore, indirect fibrinolytic effects have been attributed to FXII firstly by cleavage 
of plasminogen proactivator (31) and secondly by complex formation with plasminogen 
activator inhibitor type-1 and its subsequent inactivation (32). In line with these findings 
are the structural homologies of FXII with t-PA (12, 14). A mitogenic effect of FXII has 
been demonstrated in HepG2 cells (22), fetal alveolar cells, endothelial cells, 
epithelioid carcinoma cells and aortic smooth muscle cells (33), most likely involving 
the EGF-like domains.  
     
1.1.2.1.3 Activation and inhibition of FXII 
FXII zymogen is activated by cleavage of the Arg353-Val354 bound either during 
autoactivation or by KLK. Numerous substrates have been found to be in vitro capable 
of triggering autoactivation of FXII as kaolin (34), dextran sulfates (35), sulfatides (36-
38), bacterial lipopolysaccarides (39), heparin, chondroit sulfate (40), articular cartilage 
and calcium pyrophosphat (13, 41). Although the process of FXII activation under 
physiological conditions remains unsettled, potential activators have been identified as 
RNA (42), collagen (43) and inorganic polyphosphates (PolyP) (44). The latter has 
been observed to be released by activated platelets in vivo and induce the contact 
activation system (45).  The reciprocal KLK-driven activation of FXII with HK as 
cofactor amplifies FXIIa generation and is required for a sufficient rate to initiate the 
intrinsic clotting pathway and the kinin-kallikrein system (46, 47). The significant role of 
C1 esterase inhibitor (C1 INH) as irreversible inhibitor of FXII is generally 
acknowledged (48, 49). This serine protease inhibitor was first described in connection 
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with the first component of complement, as it was detected to inactivate the 
subcomponents C1r and C1s (50). Since then  a wide range of additional proteases 
have been identified to be target of C1 INH inactivation, among them α-FXIIa and β-
FXIIa (51). The inhibition rate is attenuated in the presence of kaolin, sulfatides and 
other negatively charged surfaces, thus α-FXIIa appears to be protected from inhibition 
when bound to a surface. Accordantly, this effect does not apply for β-FXIIa due to its 
lack of a surface binding site (52). Anti-thrombin III (AT III), α-2-macroglobulin and α-2-
antiplasmin were additionally demonstrated to have inhibiting effects on FXIIa, though 
to a much lower degree (48, 53). However, the predominant role of C1 INH is 
challenged by a study, demonstrating a preponderant complex formation of FXII-AT III, 
when FXII activation is triggered by activated platelets. This might draw new attention 
to the in vivo role of AT III as inhibitor of FXII (54). 
 
1.1.2.2   Factor XI  
The liver represents the main source of FXI synthesis. However, human FXI RNA has 
additionally been located in the kidney and pancreas, though their contribution to the 
FXI plasma level is presumed to be negligible (55).            
FXI is a zymogen of 160 kDa molecular weight, with the unique feature among 
coagulation proteases of a homodimeric structure (55-57). This homodimer contains 
two identical polypeptide chains, linked by a disulfide bond (58, 59). Each of the two 
chains is composed of a heavy and a light chain, the latter containing the catalytic 
portion with the classic triad of His, Asp and Ser as found in FXII (60). Each heavy 
chain is composed of four tandem repeats, containing 90-91 amino acid residues 
respectively, referred to as Apple domains (A1-4) (57, 60, 61). Remarkably, the amino 
acid sequence of FXI is to 58% homologous to prekallikrein (PK) (57), a discovery 
elucidated by a common evolutionary ancestor (62, 63). Both proteins share the feature 
of being substrates of FXII and are each by majority found associated in a non-covalent 
complex with HK (63, 64). The particular dimeric formation of FXI is presumed to be 
essential for the activation by α-FXIIa and thrombin (56, 65). FXIIa triggered FXI 
activation is performed by cleavage of the Arg 369- Ile 370 bond (57), an interaction found 
to involve HK as important cofactor (61, 66). FXIa possesses serine protease 
properties and activates FIX, a crucial contributor to thrombin generation (3, 67).    
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1.1.2.3  Kallikrein      
Contrary to FXI the precursor of plasma kallikrein, prekallikrein (PKLK), is of 
monomeric structure, containing 619 amino acids (68). Activation of PK is initiated by 
internal cleavage of the Arg371- Ile372 bond, resulting in formation of a heavy chain of 52 
kDa and a light chain, linked together by a disulfide bond (60, 69). Two different 
variations of the light chain were detected at 33 kDa and 36 kDa, respectively (70). 
Analogous to FXI, the heavy chain of KLK contains the four Apple domains (A1-4) of 
repeat sequences in the amino-terminal part (68). The light chain contains the 
carboxyl-terminal located catalytic domain and has similar amino acid sequences as 
the trypsin family of serine proteases (68, 70).  Further cleavage of the heavy chain of 
KLK, a process determined to be of autolytic nature, induces β-KLK generation (70, 
71). The heavy chain has been reported to be the essential site for interactions with HK 
and FXII (72, 73). Thus, regions participating in HK binding have been localized within 
the A2 domain (74) as well as in domain A1 and A4 (75) of the heavy chain. The non-
covalent complex formation with HK not only facilitates surface binding with 
subsequent enhanced activation by FXII, but further protects KLK from inhibition by its 
major inhibitors C1 IHN and α-2-macroglobulin in plasma (76, 77). Activated KLK 
cleaves HK into HKa, liberating bradykinin (BK). HKa is found to have a more 
accelerating impact as cofactor on FXII activation than its precursor (78). Additionally, 
fibrinolytic activity is attributed to KLK; directly by activation of plasminogen and 
indirectly by cleavage of pro-urokinase, a plasminogen activator (79, 80). 
 
1.1.2.4 High molecular weight kininogen (HK) 
Despite having no enzymatic activity of its own, the pathophysiological functions of HK 
are manifold and of indispensable relevance in contact activation. Firstly, HK is the 
precursor of BK, a highly significant modulator of vasodilatation and inflammatory 
response. Secondly, HK has an accelerating effect as a cofactor on contact activation. 
HK is a glycoprotein with a molecular weight of 120 kDa. It is cleaved by KLK into a 
heavy chain of 62 kDa and a light chain of 56kDa, joined together by a disulfide bond 
(60, 81-83). HK consists of six different regions, referred to as D1-D6. Whereas the 
domains D1-D3 account for the heavy chain, D4 constitutes BK, and the light chain is 
composed of the domain D5-6 (60, 81, 84). Remarkably, all contact activation pathway 
activity is linked to the light chain (76). The binding site for anionic surfaces in vitro as 
well as for endothelial cells, neutrophils and platelets, is localized on D5 of the light 
chain (84-87). D6 has been identified to contain the binding site for FXI and PK (84). 
The presence of HK during contact activation is of essential importance; besides its 
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function as an associate for FXI and KLK in plasma, it also serves as an anchor, linking 
the proteases to the surface and consequently providing ideal conditions for FXII 
triggered activation (66).   
 
1.1.2.4.1 Bradykinin 
Liberated BK, a nanopeptid of nine amino acids, is involved in a wide range of vascular 
and inflammatory processes (88, 89). The half-life of BK is briefly limited due to a rapid 
degradation by different enzymes, particularly the angiotensin-converting enzyme 
(ACE) (90, 91). Vascular modulative effects include the release of superoxide anion 
(92), prostacyclin (93), nitric oxide (NO) (94) and promotion of hyperpolarization and 
relaxation of arterial smooth muscle cells (95). Furthermore, this kinin has been found 
to stimulate the release of t-PA, thus contributing to the regulation of fibrinolysis (96, 
97). The inflammatory impact of BK is mediated through the bradykinin-1-receptor 
(B1R) and bradykinin-2-receptor (B2R). The former is exclusively expressed in 
response to inflammatory stimuli such as interleukin-1β (IL-1β) and tumor necrosis 
factor-α (TNF-α) (91). By contrast, B2R is constitutively produced (90, 91) and its 
expression is recognized to be reinforced by BK itself (98, 99). Both receptors are 
identified to be involved in BK induced recruitment of lymphocytic cells during 
inflammation (100, 101). BK stimulates the release of interleukin-8 (IL-8), granulocyte-
colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor 
(GM-CSF), monocyte chemoattractant protein-1 (MCP-1) and TNF-β in lung fibroblasts 
(101). Particularly IL-8 is an essential inflammatory mediator and a highly effective 
neutrophil chemoattractant. BK further effectuates the release of the proinflammatory 
cytokines interleukin-6 (IL-6) (102) and IL-1β (88) in airway smooth muscle cells and 
human fibroblasts via B2R.  
 
1.1.3  Cellular interaction of the contact activation system 
The finding of intrinsic components on human cells has given rise to the question 
whether these cells might serve as a platform for the proteins to assemble and 
represent the site of contact phase activation in vivo. Furthermore, a potential effect of 
contact proteins on cellular processes through receptor binding has been put into 
consideration. On the surface of human neutrophils FXII, FXI, PK and HK have been 
immune-localized (21, 103). Whereas FXII and HK bind directly to neutrophils, FXI and 
PK are attached to the cell surface through HK. Apparently, both chains of HK contain 
regions responsible for the leukocytes binding. An essential receptor for HK was 
determined to be Mac-1 (CD11b/CD18) (85), a leukocyte integrin known to be also 
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involved in neutrophil adhesion and transendothelial migration (104). The assembly of 
the contact proteins presents a potential source of BK generation attached to the 
immune cells. Considering its effect on the permeability of vessels, liberated BK might 
thereby locally promote neutrophils diathesis (21).       
The presence of the intrinsic components has also been recognized on human 
endothelial cells. Up to this day, three different receptors, namely urokinase 
plasminogen activator receptor (u-PAR), gC1qR and cytokeratin-1, have been 
identified to be targets of zinc dependent FXII and HK binding. The interaction of FXII 
with u-PAR, in complex with β1 integrin and EGFR, has been observed to stimulate 
proliferation of endothelial cells and angiogenesis (105). Of great interest is further the 
binding process of the intrinsic factors to the receptor for the C1 subcomponent of the 
first component of complement gC1qR (18, 19, 106). The binding site of the contact 
proteins within the receptor appears to differ from that of C1q, as no mutual 
interference or inhibition is observed (18). Cytokeratin-1 constitutes the third identified 
receptor and exists partly as a bimolecular complex in association with u-PAR (90, 107) 
or gC1qR (19, 90). Lastly, contact activation factors have been localized on activated 
platelets, and their enzymatic activity while being bound to thrombocytes has been 
demonstrated (44, 54). Thus, platelets may also provide a platform for the activation 
and activity of contact pathway proteases.    
 
1.1.4  The role of contact activation in hemostasis and thrombosis 
The negligible contribution of intrinsic pathway factors to thrombin generation during 
hemostasis has been acknowledged in the past decades of research, mainly based on 
the objective fact that FXII deficient patients do not suffer of a bleeding disorder. More 
recently, data have been published which are consistent with this perception, but 
indicate an essential contribution of the proteases in pathological thrombus formation. 
This hypothesis was supported by the finding that FXII deficient (FXII-/-) mice were 
protected from thrombus formation after artificially induced vessel injury. This protective 
effect was rescinded after FXII infusion, confirming the favorable effect of FXII 
deficiency (108, 109). Defective thrombus formation in FXII -/- mice was also noticed for 
cerebral ischemia models, further highlighting a predominant role of FXII in thrombosis 
(110), (109, 111). These antithrombotic effects in FXII -/- mice were observed not to be 
limited to FXII. Similar results were found in FXI deficient (FXI-/-) mice, expanding a 
potential role of pathological thrombus formation to the intrinsic cascade (112, 113). 
Considering their lack of interference with physiological hemostasis, the intrinsic factors 
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might provide optimal conditions for thrombosis prevention. However, to date this 
antithrombotic effect of FXII depletion has not been established for humans.   
 
1.1.5  The role of contact activation in inflammation 
Research of the recent decades indicates an essential importance of the contact 
pathway as modulator of inflammatory processes. In this context, FXII and KLK have 
been found to be capable of attracting neutrophils and inducing their aggregation (114-
116). Moreover, both proteases were demonstrated to promote the degranulation of 
neutrophils and the subsequent release of neutrophil elastase (116-119). The pro-
inflammatory attribute is further emphasized in a study showing that inhibition of FXII in 
septic baboons resulted in declining activation of the complement system and reduced 
release of neutrophil elastase and IL-8 (118). Additionally, FXII has been reported to 
have a reinforcing effect on cytokine expression, stimulating the synthesis of IL1-β in 
monocytes (115). A potential impact on septic conditions has been also described for 
FXI, thus inhibition of this protease was noted to attenuate inflammation and improve 
survival of affected mice (120). However, the crucial contribution of contact activation to 
inflammation emerges to be the HK-derived liberation and rapid provision of BK, the 
key participant in a broad diversity of inflammatory disorders (121).  
 
1.2  C1 esterase inhibitor 
C 1 esterase inhibitor (C1 INH) is a single chain glycoprotein, belonging to the family of 
serine protease inhibitor (serpins). The inhibitor has a molecular weight of 105 kDa and 
is exceptionally heavily glycosylated. Two domains can be distinguished; the carboxyl 
terminal located serpin domain represents the site of its inhibitory activity, containing 
the protease recognizing compartment, also called the reactive center loop (122, 123). 
The interaction of the active serine of the target protease with the serpin domain of C1 
INH results in an irreversible complex formation with disruption of the molecular 
structure of the protease (124). The second domain of C1 INH is the particularly richly 
glycosylated amino terminal domain, which is unique to the inhibitor and has been 
acknowledged to be not involved in its protease inhibitory activity (123). Having an 
extended range of substrates within the coagulation, fibrinolytic and complement 
activation system, C1 INH represents a serpin of high biological relevance. A 
particularly critical role is assigned to the inhibitor as important regulator of 
inflammation as C1 INH is the exclusive inhibitor of the classic pathway of complement 
and manifested to be the main inhibitor of FXII and KLK of the contact system. 
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Proteolytical cleavage of C1 INH in the reactive center causes the inactivation of its 
protease inhibitory activity. An enzyme identified among others to be capable of C1 
INH inactivation is the neutrophil elastase, an important participant in a wide range of 
inflammatory diseases, including the acute respiratory distress syndrome (125).  Aside 
from its extended significance as inhibitor of plasma proteases, C1 INH has been 
recognized to directly interact with endothelial and immune cells and may therefore 
contain additional anti-inflammatory attributes independent from its activities as plasma 
protease inhibitor (122, 126, 127). Heterozygous C1 INH deficiency results in 
hereditary angioedema (HAE), a disease with the clinical pattern of sudden phases of 
increased vasopermeability with severe edema formation mediated by unrestricted BK 
generation (122).    
  
1.3  Acute respiratory distress syndrome  
Acute respiratory distress syndrome (ARDS) is a lung disease of inflammatory nature, 
commonly culminating in fibroproliferative tissue remodeling and fibrotic alteration of 
the lung. Over the past decades, a high discrepancy has been reported in trials 
investigating the incidence of ARDS. These controversial observations may partly be 
explained by a deviation of the definition of the disease, recent improvements in 
medical treatment and regional differences.  An incidence of 58.7/100,000/year was 
stated in an extensive investigation including 21 hospitals in the United States. Milder 
variations of lung injury were estimated to account for 78.9/100,000/year. Furthermore 
the incidence and mortality was found to be highly dependent on the age of the 
patients (128). A more limited incidence has been reported in European trials (129-
131), for example a rate of 7.2/100,000/year was acknowledged in Spain (131). In line 
with these data, a recent retrospective evaluation in Iceland stated the incidence of 
ARDS at a similarly low level (130). Additionally, this study revealed a steady increase 
of 0.2 cases/year from 1988 to 2010 (130). Though various approaches concerning the 
treatment of ARDS have been made, only lung protective ventilation has proven to 
have a beneficial effect on survival (132). Thus, despite a declining trend (130, 133) 
mortality still remains high, varying between 33% (130)  and 47.8% (131).  
 
1.3.1  Definition and etiopathology of ARDS 
The definition of ARDS has undergone multiple alterations and concisions since first 
described in 1967 by Ashbaugh. This first definition included a severe respiratory 
distress associated with hypoxemia refectory to oxygen therapy, a decline of lung 
compliance and diffuse lung infiltration appearing and rapidly spreading in the chest 
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radiograph (134). Intending to specify and internationally standardize the ARDS term, 
the American-European-Consensus Conference Committee (AECC) redefined the 
criteria of the disease in 1994. This recommendation is the currently prevalent utilized 
definition of ARDS, differentiating according to the degree of hypoxemia:                                                                                                                                                                                                                                                                                                          
A mild type, named acute lung injury (ALI) and a severe type called the acute 
respiratory distress syndrome (ARDS), using the ratio of partial pressure of arterial 
oxygen to fraction of inspired oxygen (PaO2 / FiO2) as criterion for the degree of 
hypoxemia. Thus, hypoxemia with a PaO2/ FiO2 < 300mmHg is classified as ALI, a PaO2/ 
FiO2 <200 mmHg as ARDS (135). Additionally, diseases with similar symptoms, but 
chronic course, were excluded from the definition. The pulmonary artery wedge 
pressure was determined to be less than 18 mmHg or absence of clinical signs of left 
atrial hypertension must be verified, excluding cardiac failure as origin of the 
symptoms. Radiologically, bilateral infiltration in the front chest radiograph was 
advocated to be a dispositive criterion for ALI/ ARDS (135). 
The latest definition published, referred to as the Berlin Definition further specifies 
these criteria. Accordingly, it is suggested to differentiate three different categories, 
mild (PaO2/FiO2= 200-300 mmHg), moderate (PaO2/FiO2 =100-200mmHg) and severe 
(PaO2/FiO2 <100 mmHg) ARDS, based on the degree of hypoxemia, also stating the 
Positive Expiratory End Pressure (PEEP) at a minimum of 5 cmH2O. Furthermore, the 
acute onset was concretized, determining a period of less than one week (136).  The 
pulmonary wedge pressure was eliminated from the definition to avoid exclusion of 
ARDS patients with coexisting heart failure. Instead, patients with a diseased heart and 
clinical signs respective to the criteria of ARDS are included into the definition, when 
the extent of respiratory distress is not to be explained by cardiac failure only. The 
report proposes in such cases further clinical efforts to clearly identify the origin of the 
edema causing the respiratory distress (136). Etiologically, two different kinds of ARDS 
are to be distinguished. Direct ARDS is based on pulmonary genesis, most commonly 
as a result of a pulmonary infection, but also after aspiration, nearly-drowning or 
inhalation of toxic gas (130, 131). By contrast indirect ARDS has an extrapulmonary 
source and may occur as accompanying complication during sepsis, acute pancreatitis 
and blood transfusion (132, 137). 
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1.3.2  Pathogenesis of ARDS 
The pathogenesis of ARDS is a complex and not entirely explored process, involving a 
high diversity of biochemical components contributing to the alterations of the lung 
tissue. Initially, the pathological characteristic is acute inflammation, accompanied by 
injury of the endothelial and epithelial alveolar membrane (132, 138). The permeability 
of the alveolar barrier increases, leading to influx of protein-rich fluids, which results in 
interstitial and alveolar edema (132, 137). In this period, a high amount of 
proinflammatory mediators notably secreted by alveolar macrophages are found in 
bronchoalveolar lavage fluids (BALF), as IL-1β, IL-6, IL-8 and TNF- α (132, 139). 
Elevated plasma levels of IL-1β and IL-6 have been found to be predictors of poor 
outcome, correlating with a high mortality rate (140-142). The particular significance of 
IL-8 as chemotactic stimulant has thoroughly been explored (139, 140). Along with the 
keratinocyte-derived chemokine (CXCL1) and macrophage inflammatory protein 2 
(MIP-2) IL-8 is part of a complex network leading to excessive neutrophil activation and 
abundant neutrophil recruitment from capillaries via interstitium into the alveolar space 
(140, 143). Under these pathological conditions the infiltrating neutrophils release 
various proinflammatory mediators (132, 140). In particular, the neutrophil elastase has 
been focus of several investigations revealing a critical role of the enzyme in the 
pathology of ARDS (140, 144, 145). Besides, also other neutrophil-derived mediators 
as matrix metalloproteinases, cationic peptides and oxidants are identified to contribute 
to the pathogenesis of ARDS (140, 144). Accordingly, α-defensin, a cationic peptide 
synthesized by neutrophils and stored in granules, increases the alveolar endothelial 
and epithelial permeability and boosts neutrophil activation when set into extracellular 
space (146).   
At this stage, the main histological feature is diffuse alveolar damage and a denuded 
basement membrane with formations of hyaline membranes, consisting of fibrin 
deposits (132, 147, 148). The destruction of alveolar cells, causing a decline of the 
normal epithelial fluid transport, aggravates the alveolar edema and prohibits its 
resolution (132). Physiologically, type I cells constitute 80% of the alveolar surface. 
Their loss within the inflammatory destruction is compensated by type II cells, which 
differentiate into type I to cover the denuded membrane. In consequence surfactant 
production, an ability mainly inherent to type II cells, is reduced. Deficiency of 
surfactant leads to an increased surface tension, precipitating atelectasis (132, 140, 
149). This effect is reinforced by a decrease of functional surfactant due to its 
contamination with protein-rich fluids (150). The acute, exsudative phase merges into a 
fibroproliferative process hallmarked by alveolar type II and fibroblast proliferation with 
excessive deposition of fibrin, fibronectin and collagen (151-153). The ancient 
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perception that this proliferative phase is a late feature of ARDS has been challenged 
by investigations, demonstrating an elevation of procollagen peptide III, an early 
marker of collagen synthesis, from the third day onwards (154). This finding makes it 
reasonable to conclude that fibroproliferative alteration occurs simultaneously with the 
inflammatory response, rather than subsequently (153).  Activated fibroblasts are found 
to migrate into the interstitium as well as into the intra-alveolar space and excessively 
release collagen and other extracellular matrix proteins. This contributes to the 
development of diffuse fibrosis, resulting in alveolar obliteration and diminution of 
pulmonary compliance (148, 151, 153). Interestingly, the individual course of ARDS 
appears heterogeneous and complete resolution subsequent to the inflammatory 
phase occurs in other patients (132). In this regard, genetic disposition is suspected to 
have essential influence on the susceptibility and course of ARDS (155). Some 
uncertainties remain concerning the pathogenesis of ARDS. For instance, only some 
mediators contributing to the development of fibrosing alveolitis are yet identified. 
Transforming growth factor-β1 (TGF-β1) is well recognized to be an essential factor to 
initiate collagen synthesis and deposition as well as fibroproliferation in the  lung (151, 
156-158) and found to be elevated in BALF of ARDS patients (157). 
Also mediators affiliated to the inflammatory response, such as TNF-α and IL-1β, have 
been identified as contributive to the genesis of fibrosis (159-161), most likely by 
inducing TGF-β1 (161). Furthermore, another significant factor promoting fibrin 
deposition and fibrosing alteration of the lung is the unbalanced state of hemostasis in 
favor of procoagulation and antifibrinolysis (152, 162-167).  
 
1.3.3  Alveolar coagulation in ARDS  
1.3.3.1 The role of extrinsic coagulation factors in ARDS 
A striking imbalance in alveolar hemostasis is detected in lungs of ARDS patients. 
Within the scope of animal studies, a significant increase of procoagulant activity is 
observed, while fibrinolytic efficiency has been noted to be reduced (162, 163). 
Correspondingly, extrinsic pathway activity has been found to be elevated in BALF of 
ARDS patients with concurrent inhibition of fibrinolytic activity by diminishment of 
urokinase-type plasminogen activator and increased plasminogen-activator inhibitor-1 
levels. These conditions are observed, regardless of whether the acute respiratory 
distress syndrome is due to pulmonary or non-pulmonary causes (162). It is worthwhile 
noting that a comparable hemostatic status also applies for patients with severe 
pneumonia, who are spontaneously breathing. Thus, the assumption of the hemostatic 
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imbalance being only due to ventilator treatment can be dismissed, eliciting the idea of 
a pathological role of the elevated coagulant factors in lung injury (162). In line with this 
conclusion, attenuation of lung injury is observed in animal studies, when the 
procoagulant state is restrained by competitive inhibition of the tissue factor, the 
initiator of the extrinsic pathway. Furthermore, the blockade precipitates a decrease of 
local pro-inflammatory cytokines as IL-1β and IL-6 (168), underscoring the hypothesis 
of an inflammatory impact of coagulation factors and a pathological accountability 
beyond fibrin deposition in ARDS (165, 169). This assumption is supported by further 
research, confirming pro-inflammatory effects of coagulation factor Xa and thrombin 
(169-171), mainly linked to interactions with the protease-activated receptor (PAR)-1 
(167, 169, 172, 173). This reinforcing effect between coagulation and inflammation 
mediators appears to be reciprocal as, for example, the tissue factor activation is 
stimulated by cytokines as TNF-α and IL-6 (174).            
The preponderance of procoagulant activity results in abundant fibrin deposition, 
potentially culminating in interstitial and intra-alveolar fibrosis (152, 153, 162, 163, 167). 
Fibrin and its degrading products were found not only to have inflammatory attributes 
by inducing neutrophil recruitment (175, 176), but additionally they were reported to 
stimulate fibroblast migration and proliferation (177). Besides the fibrin deposition as 
consequence of boosted extrinsic pathway activity, factor Xa (FXa) and thrombin 
further contribute to the fibrotic alteration to the lung. Thus, both proteins are identified 
to stimulate procollagen synthesis in fibroblasts putatively via PAR-1 (178, 179) and to 
contain mitogenic effects on fibroblasts (180, 181).  
 
1.3.3.2 The role of intrinsic factors in inflammation and fibrotic alteration of the  
   lung 
The focus of previous studies regarding the contribution of coagulation factors to lung 
inflammation and remodeling has commonly been on extrinsic factors rather than on 
proteins of the intrinsic pathway. Nevertheless, there is growing evidence of an 
underestimated relevance of intrinsic coagulation factors in the pathogenesis of lung 
injury. Thus, recent studies investigating a potential pathological contribution of intrinsic 
factors on Idiopathic Pulmonary Fibrosis (IPF) and murine bleomycin-induced lung 
injury, revealed a profibrotic activity of FXII related to its mitogenic activities towards 
human and mice lung fibroblasts (182). Within the scope of this investigation, a 
protection from bleomycin-induced lung fibrosis was noted in FXII deficient mice as well 
as in mice with inhibition of FXII by corn trypsin inhibitor (CTI). This profibrotic effect of 
FXII was independent of fibrin generation as no difference in fibrin disposition was 
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found compared to wild type (WT) mice (182, 183). Thus, a contribution of contact 
activation rather based on its pro-inflammatory and mitogenic properties during the 
pathogenesis of fibrotic lung diseases seems reasonable.    
Pro-inflammatory attributes of FXII and KLK have been demonstrated in cultured cells 
and animal studies (115, 117-119).  In line with these findings, a preventive effect in 
lung injury caused by Salmonella was observed when FXII and KLK were inhibited 
(184), illustrating a putative role of these factors not only in sepsis, but also in lung 
injury. Worthwhile mentioning is further the discovery of an inducing effect of TGF-β on 
FXII gene transcription in fibroblasts. Considering the elevated level of TGF-β in ARDS 
patients (157) and its established role in inflammatory and fibrotic processes in lung 
injury (156, 158, 185), the hypothesis of a contributing effect of FXII on ARDS 
pathogenesis gains further support. A possible stimulus for FXII activation in ARDS 
might be extracellular RNA, released from dying cells (42).  
Given the extended involvement of BK in inflammation, great interest arises in the 
potential role of this contact activation product in the pathogenesis of ARDS. BK is well 
acknowledged to contain chemotactic features and might therefore promote neutrophil 
migration into the lung as found during the course of the disease. Particularly the 
stimulating effect of BK on human lung fibroblasts and airway epithelial cells to release 
chemokines has been demonstrated (99, 101). Furthermore, administration of inhibitors 
of either receptor of BK has led to attenuation of pulmonary leukocyte accumulation 
(100). Thus, BK is a pivotal intermediary during different inflammatory processes in the 
lung and it appears imperative to determine its putative role in the pathology of ARDS.  
It seems reasonable to conclude that the perception of a functional role of coagulation 
factors limited on blood hemostasis is obsolete. Numerous cellular effects beyond 
coagulation have been found to be induced by coagulation proteases and a 
considerable impact on the development of inflammation and proliferation up to fibrotic 
tissue remodeling has been observed. Therefore the consideration of a critical role of 
coagulation factors in lung injury in general, and ARDS in particular, appears 
indispensable. Previous investigations support the idea of a pathological contribution of 
extrinsic pathway proteins on the pathological process in chronic and acute lung 
diseases, including ARDS. However, the research regarding a potential role of the 
contact pathway in severe lung injury and subsequent lung tissue remodeling is as yet 
in the initial stage.  
 
The objective of the present study is to investigate the occurrence and properties of the 
contact pathway components in the pathogenesis of ARDS and in bleomycin-induced 
lung injury in mice. The incidence of FXII, KLK, HK, BK and FXI, respectively, was 
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examined in clinical as well as in animal samples. The possible therapeutic 
consequences of the inhibition of contact phase proteins were studied in a murine 
model of lung injury.  The main emphasis of this study is on FXII, the initiator of intrinsic 
coagulation and the kinin-kallikrein system, and its potential contribution to the 
pathogenesis of ARDS.  
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2.  Materials and methods 
2.1  Materials 
2.1.1  Apparatuses and Equipments 
 
Centrifuge  Mikro20, Hettich GmbH, Tuttlingen, 
Germany                
Centrifuge II  Heraeus Labofuge 400R, Functional line, 
ThermoFisher Scientific, Waltham, MA 
Electrophoresis chambers   Biometra, Göttingen, Germany 
Falcon tubes                                       Greiner Bio-One, Frickenhausen, Germany 
Film cassette     Kodak, Rochester, NY 
Filter tips     Eppendorf, Hamburg, Germany 
Pipetboy     Eppendorf, Hamburg, Germany 
Pipets      Eppendorf, Hamburg,Germany 
Power Pac 1000    BIORAD, Hercules, CA 
PVDF membrane    Amersham Biosciences, Little Chalfont, UK 
Radiographic film    Amersham Biosciences, Little Chalfont, UK 
SpectraMax 190  Molecular Devices, Silicon Valley, CA 
StepOne Real time PCR System  Life Technologies, Carlsbad, CA 
Thriller Thermoshaker-incubator  PeQlab, Erlangen, Germany 
Vortex machine    VWR, Darmstadt Germany 
Western blot chambers   Biometra, Göttingen, Germany 
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2.1.2 Reagents 
Acrylamide solution    Roth, Karlsruhe, Germany 
Agarose     Roth, Karlsruhe, Germany 
Ammonium persulfate   Sigma-Aldrich, St-Louis, MO 
Albumine, bovine serum   Sigma-Aldrich, St-Louis, MO 
Biocoll      Biochrom, Cambrige, UK 
β-mercaptoethanol    Sigma-Aldrich, St-Louis, MO 
EDTA      Sigma-Aldrich, St-Louis, MO 
Ethanol     Roth, Karlsruhe, Germany 
Ethidium bromide    Sigma-Aldrich, St-Louis, MO 
Glycerol     Roth, Karlsruhe, Germany 
Glycine     Roth, Karlsruhe, Germany 
Hematoxylin     Roth, Karlsruhe, Germany 
HEPES     Roth, Karlsruhe, Germany 
Hydrochloric acid    Roth, Karlsruhe, Germany 
Methanol     Roth, Karlsruhe, Germany 
Milk powder     Roth, Karlsruhe Germany 
Phenylmethylsulfonylflourid   Sigma-Aldrich, St-Louis, MO 
Potassium chloride    Roth, Karlsruhe, Germany 
Potassium phosphate monobasic  Sigma-Aldrich, St-Louis, MO 
Skim Milk powder    Sigma-Aldrich, St-Louis, MO 
Sodium bicarbonate    Sigma-Aldrich, St-Louis, MO 
Sodium chloride     Sigma-Aldrich, St-Louis, MO 
Sodium carbonate    Roth, Karlsruhe, Germany 
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Sodium deoxycholate   Sigma-Aldrich, St-Louis, MO 
Sodium dodecyl sulfat (SDS)  Sigma-Aldrich, St-Louis, MO 
Sodium hydroxide    Sigma-Aldrich, St-Louis, MO 
Sodium phosphate dibasic   Sigma-Aldrich, St-Louis, MO 
TEMED     Sigma-Aldrich, St-Louis, MO 
Tris      Roth, Karlsruhe, Germany 
Triton-X-100     Sigma-Aldrich, St-Louis, MO 
Tween 20     Sigma-Aldrich, St-Louis, MO  
Xylene      Roth, Karlsruhe, Germany 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and methods 
 
- 20 - 
 
2.1.3 KITs 
AssayMax FXII ELISA KIT   Assaypro, Saint Charles, MO 
Matched Pair Antibody Set for FXII  Affinity Biologicals, Ancaster, Canada 
Human Bradykinin ELISA KIT  Cusabio Biotech Co., Wuhan, China 
PeqGOLD Total RNA Kit                          PeqLab, Erlangen, Germany 
Permanent AP Red Kit   Zytomed Systems GmbH, Berlin,   
      Germany 
Pierce BCA Protein Assay Kit  Thermo Fisher Scientific, Waltham, MA 
Pierce ECL Plus WB Substrate                     Thermo Fisher Scientific, Waltham, MA 
Zyto-Chem-Plus AP Polymer-Kit   Zytomed Systems GmbH, Berlin, Germany 
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2.2  Methods 
2.2.1  Test samples 
2.2.1.1 Study Population 
The human BAL 
F samples were obtained from 46 consecutive mechanically ventilated ARDS patients 
admitted to the intensive care unit of Department of Internal Medicine, Pneumology and 
Intensive Care Medicine at the University of Gießen. All patients met the criteria of the 
American-European Consensus Conference on ARDS (135), 28 were suffering from 
direct ARDS (Pneumonia, n=26; gastritic aspiraton, n=2) and 18 of indirect ARDS 
(sepsis, n=13; trauma/surgery, n=3; pancreatitis, n=1; polytransfusion, n=1). From the 
first day after diagnosis onward to day 8 BALF was obtained by flexible fiberoptic 
bronchoscopy at several different times. The control group was composed of 20 
healthy, spontaneously breathing volunteers and ten mechanically-ventilated patients 
with cardiogenic pulmonary edema (CLE).  
 
                                                                  
  a) 
Cardiogenic pulmonary edema; 
b) 
PaO2 : Partial pressure of oxygen in arterial blood;  
  FiO2: Fraction of  inspired oxygen   
  Table 2.1 Study population for BALF samples. 
 
 
 
The plasma samples were collected from ARDS patients (n=26) hospitalized at the 
University Clinic of Gießen and from healthy volunteers serving as controls (n=19) 
Blood leukocytes were isolated from 6 ARDS patients and 10 healthy subjects. 
Furthermore, the lung homogenate of 7 ARDS patients was obtained by autopsy. As 
the control the lung specimens of 6 patients were utilized of whom 5 had died of 
myocardial infarction and 1 of drug intoxication. Institutional approval was provided for 
all experiments involving human specimens by the Ethics Committee of the Faculty of 
Medicine of the University of Gießen. 
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2.2.1.2 Murine samples  
2.2.1.2.1 Bleomycin administration 
In all experiments 8 to 10 week old mice (C57BL/6NJ) were used. Bleomycin (Hexal, 
Holzkirchen, Germany) was applied by microsprayer (Penn-Century Inc., Philadelphia, 
PA) as a single dose of 5 U/kg bw. Age and sex-matched controls received saline. 
After 5 and 10 days, respectively, of bleomycin application, the mice were sacrificed 
with a lethal dose of pentobarbital. Bronchoalveolar lavage fluid (BALF) was collected 
and the lung tissue was either prepared for the histological examination or shock frozen 
for RNA or protein extraction.  The animals were kept according to NIH guidelines and 
the experiments were undertaken with the permission of the local authorities.  
 
2.2.1.2.2 C1 INH administration 
Starting on day 1 post bleomycin or saline administration, respectively, the animals 
were daily treated with intraperitoneal C1 INH (500 µg/ mouse; CSL, Behring GmbH, 
Marburg, Germany) administration until they were sacrified on day 5. For the control 
group 0.9% NaCl was used as vehicle. Subsequently, murine BALF was obtained and 
lung homogenate prepared for histological assessment and RNA extraction was 
performed for real-time PCR.  
 
2.2.1.2.3 Histological staining 
Murine lung tissue was formalin fixed and embedded in paraffin blocks, which were 
sectioned into 5 micrometer and transferred onto microscope slides. Prior to the tissue 
staining the samples were deparaffinized and rehydrated using xylene and alcohol of 
descending concentrations (100%, 96%, 70%, 50%). Hematoxylin-eosin staining was 
performed to visualize the histological structure and inflammatory alteration of the 
tissue. The slides were scanned with Mirax Desk Digital Slide Scanner (Zeiss, 
Göttingen, Germany) and assessed using the Mirax Viewer (Zeiss).  
 
2.2.1.2.4 Wet-to-dry lung weight ratio  
The wet-to-dry weight ratio was evaluated by the gravimetric analysis to assess the 
degree of the alveolar oedema. Initially the weight of the wet left lobe was measured 
and then incubated at 60°C for 72h. The dried lung was then again weighted and the 
ratio between the wet and the dry left lobe was determined. 
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2.2.1.2.5 Flow cytometry 
For identification of different cell phenotypes in murine BALF multicolour flow cytometry 
analysis was performed. To detect the neutrophils and other cell populations the 
following fluorochrome-conjugated surface antibodies were applied: CD11c, siglec-F, 
F4/80, GR1, CD 11b and CD11c. Following to the addition of the antibodies, the 
samples, after pretreatment with 10% (v/v) mouse serum were then incubated for 45 
minutes in darkness on ice. Prior to flow cytometry the samples were washed using 
compositions of PBS.  The analysis was then conducted using the FACS Canto II flow 
cytometer (Becton Dickinson, San Joe, CA). 
 
2.2.2  Western Blot 
For determination of the contact activation proteins in lung tissue, BALF and plasma, 
Western blotting was performed for murine and human samples. 
 
2.2.2.1 Preparation of the samples for gel electrophoresis 
Up till then stored at – 80°C, the lung tissue samples were initially lysed in Radio 
Immuno Precipitation Assay (RIPA) buffer [50 mM Tris-HCl, pH 7.4, 150 mM NaCl,       
1 mM EDTA, 1% (v/v) Triton-X-100, 1% (w/v) sodium deoxycholate, 0.1% (w/v) sodium 
dodecyl sulfate (SDS)], supplemented with protease inhibitors [1 mM PMSF, 1 µg/ml 
complete protease inhibitor cocktail (Roche Applied Science, Penzberg, Germany)] and     
1 mM Na3VO4. Afterwards the samples were incubated for 30 minutes on ice and then 
centrifuged for 10 minutes at 10 000 rpm at 4°C. Supernatants were collected and 
protein concentration was measured using the Assay BCA Protein Kit (ThermoFisher 
Scientific, Waltham, MA) according to the manufacture´s instruction. The 
measurements were executed with the microplate photometer (SpectraMax 190, 
Molecular Devices, Silicon Valley, CA). To each sample of 20 µg proteins 5 µl of 5x 
SDS-loading buffer [0.25 M Tris-HCl, pH 6.8, 10% (w/v) SDS, 50% (v/v) glycerol, 10% 
(v/v) β-mercaptoethanol] was added. The mixture was then heated at 98 °C for 10 
minutes (Thriller Thermoshaker-incubator, peQlab, Erlangen, Germany) followed by 
centrifugation. Plasma and BALF samples had also been stored at -80°C and were 
slowly thawed on ice before 20 µl of each samples was mixed with 5 µl of 5x SDS-
loading buffer.  
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2.2.2.2 Sodium dodecyl sulfate polyacrylamid gel electrophoresis 
Sodium dodecyl sulfate polyacrylamid gel electrophoresis (SDS PAGE) was utilized to 
separate the proteins according to their molecular weight. Firstly, a discontinuous SDS 
Polyacrylamid gel was prepared, consistent of a lower separating gel [resolving gel 
(10%): 10% acrylamide: bisacrylamide, 375 mM Tris-HCl, pH 8.8, 0.1% (w/v) SDS, 
0.1% (w/v) ammonium persulfate (APS), 0.1% (v/v) tetramethylethylenediamine 
(TEMED)] and a laminating stacking gel [stacking gel  (4%): 4% acrylamide: 
bisacrylamide, 125 mM Tris-HCl, pH 6.8, 0.1% (w/v) SDS, 0.1% (w/v) APS, 0.1% (v/v) 
TEMED]. After polymerization the prepared samples and 5 µl of protein marker (Page 
Ruler, Prestained Protein Ladder, ThermoFisher Scientific, Waltham, MA) were applied 
upon the gel.  
The proteins were then separated in SDS-running buffer [25 mM Tris, 250 mM glycine, 
0,1 % (w/v) SDS] via electrophoresis at a voltage of 100 V (Power Pac 1000, Biorad, 
Hercules, CA). 
 
2.2.2.3 Immunblotting 
The separated proteins were electrotransferred from the gel onto a PVDF membrane 
(Amersham Biosience, Little Chalfont, UK). This transfer was performed in blotting 
buffer [25 mM Tris, 192 mM glycine, 20% (v/v) methanol] at a voltage of 100 V for 1 
hour and was proceeded on ice. Blockage of non specific binding sites was achieved 
by incubation of the membrane with 5% (w/v) Skim Milk Powder in Tris-Buffered Saline 
containing Tween 20 [TBS-T (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% (v/v) 
Tween 20)]. Afterwards the membrane was washed with TBS-T and then incubated 
overnight at 4°C with one of the following primary antibodies: goat anti-FXII (Zytomed 
Systems, Berlin, Germany, dilution 1:1000); goat anti-FXI (Abcam, Cambridge, UK, 
dilution 1:1000); rabbit anti-KLK (Zytomed Systems,dilution 1:1000); rabbit anti-HK 
(Abcam, dilution 1:1000). All primary antibodies were diluted in 1% (w/v) bovine serum 
albumin (BSA) in TBS-T. After washing with TBS-T, the membrane was incubated with 
the peroxidase-labeled secondary antibody (all from Dako, Gostrup, Denmark, dilution 
1:3000 in 5% (w/v) Skim Milk Powder in TBS-T) for 1 hour at room temperature. Final 
detection of proteins was performed using the ECL Plus Kit (Amersham Bioscience). 
To determine the amount of protein loaded on the gel, the membrane was stripped in 
stripping buffer (100 mM glycine, 0.32% (v/v) HCl ) and reprobed with mouse β-actin 
antibody (Sigma- Aldrich, St. Louis, MO, dilution 1:10000).  
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2.2.3 Enzyme linked immunsorbent assay (ELISA) 
Further quantitative analysis targeting Factor XII and BK was performed by an Enzyme 
Linked Immunsorbent Assay (ELISA). For FXII detection in human BALF Matched Pair 
Antibody Set for FXII (Affinity Biologicals, Ancaster, Canada) was utilized and 
AssayMax Human Factor FXII (Assay Pro, Saint Charles, MO) for human plasma 
samples. BK determination was implemented with the Human Bradykinin (BK) ELISA 
Kit (Cusabio Biotech, Wuhan, China). Each assay was executed precisely in 
accordance with the respective manual instruction. 
 
2.2.3.1 FXII detection in BALF 
The microtiter plates were coated with FXII capture antibody diluted in coating buffer 
(1:100) over night at 4°C. The content of each well was decanted before they were 
filled with 150 µl of blocking buffer to prevent unspecific binding. Blockage was 
executed for 90 minutes at room temperature. This was followed by a diligent washing 
procedure with washing buffer, repeated 3 times. The thorough removal of fluids after 
every washing step was realized by subsequent tapping of the plate on absorbent 
paper towels. The standard´s were prepared as recommended by the manufacture with 
0.9% NaCl serving as diluent. Into each well 50 µl of the standards and samples were 
pipetted. Incubation was performed for 1 hour at room temperature with a following 
washing procedure. The peroxidase conjugated detecting antibody was then 
administered at a dilution of 1:100. After 1 hour of incubation, another washing step 
was executed. For visualization of the peroxidase activity 3,3′,5,5′-tetramethylbenzidine 
(TMB) Substrate (Thermo Scientific) was added. The color generating reaction was 
interrupted by addition of 2 M H2SO4 after 5 minutes. The concentration of the target 
protein was then determined by quantification of the optical density in the microplate 
reader (SpectraMAX 190) at 490 nm. 
 
2.2.3.2 FXII detection in plasma 
The AssayPro Kit provided microplates precoated with murine FXII antibody. The 
standards and samples were therefore directly administered at a volume of 50µl into 
each well. Prior to the performance of the assay the optimal dilution factor for the 
plasma samples had been determined in a test run to be 1:2000. The EIA Diluent of the 
Kit served as diluting agent. The incubation was then executed at room temperature for 
2 hours. This was followed by a washing sequence, which was repeated 5 times as 
prescribed in the manual with subsequent thorough removal of residual liquids. Then 
50 µl of biotinylated FXII antibody diluted in EIA Diluent (1:100) was added and 
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incubated for 1 hour. After another washing step, 50 µl of peroxidase conjugated 
Streptavidin was pipetted into each well. Possessing a particularly high affinity to biotin, 
Streptavidin binds to the biotinylated FXII antibody. Unbound material was eliminated 
after 30 minutes by another washing procedure. Peroxidase activity was then 
expressed by addition of the chromogen substrate TMB. After 10 minutes, a 0.5 N HCl 
stopped the chromogen substrate reaction. The absorbance was determined at a 
wavelength of 450 nm. 
 
2.2.3.3 BK detection in BALF and plasma 
The microtiter plates for BK detection were delivered pre-coated. Initially, the optimal 
dilution of the plasma samples was determined in a test run to be 1:400. 
Corresponding to the FXII assay, BALF samples were not diluted. The standards were 
prepared as advised by the manual. In each well 100 µl of standard and samples were 
administered and incubated for 2 hours at 37°C (Hereaus Function Line Incubator, 
ThermoFisher Scientific). The fluids were then decanted. Biotinlyated antibody was 
added and incubated at 37°C for 2 hours. After removal of the antibody working 
solution, a volume of 200 µl washing buffer was filled into each well. After 2 minutes 
the washing solution was completely removed by aspiration of the fluids and 
subsequent patting of the plate on a paper towel. This process was repeated 3 times. 
Then 100 µl of HRP-avidin was applied into each well and incubated for 1 hour at 
37°C. A washing step followed, this time repeated 5 times in a row. TMB Substrate was 
added and after 20 minutes the color forming reaction was interrupted by 2 M H2So4. 
The color generated was quantified at a wavelength of 450 nm. 
 
2.2.4 Isolation of leukocytes 
Blood samples were collected in 7.5 ml EDTA-tubes and mixed with the same amount 
of PBS. This mixture was prudently placed upon 14 ml Biocoll 2 400 rpm (Biochrom 
AG, Berlin, Germany), followed by 30 minutes of centrifugation at room temperature 
separating the blood components into different phases. Forming a thin layer above the 
plasma phase, leukocyte phase was extracted and collected in a tube. 45 ml PBS was 
added at a subsequent speed of 1 500 rpm for 10 minutes with brake. Supernatant 
liquids were removed. In case of contamination with erythrocytes, 1 ml of ultra pure 
water (Mini Plasco connect, B.Braun, Melsungen, Germany) was added into the tube 
and swiveled for a few seconds. Subsequently, 9 ml of PBS was added. This was 
followed by 10 minutes of centrifugation at 1 500 rpm at room temperatur. Supernatant 
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fluids were discarded from the leukocyte pellet. Isolated leucocytes were used for RNA 
isolation. 
 
2.2.5 Molecular Analysis 
2.2.5.1 RNA Isolation  
The pellet of isolated leucocytes was thoroughly mixed with 400 µl of RNA lysis buffer 
(PeqGOLD Total RNA Kit, PeqLab, Erlangen, Germany). After incubation the fluids 
were run through a DNA column for 1 minute at 12 000 rpm (Mikro 20, Hettich GmbH, 
Tuttlingen, Germany). 400 µl of Ethanol was added to the flow through and vortexed. 
The fluids were then placed on a RNA column and centrifuged for 1 minute at 12 000 
rpm. This was followed by a washing treatment including 3 steps with the solutions 
provided by the Kit with subsequent centrifugation for 15 seconds, respectively. The 
column was dried in a following spin and then transferred to a sterile collection tube 
and RNA free water was applied to the column and incubated for 2 minutes. Then at 5 
000 rpm the RNA was eluted for 1 minute. The RNA concentration was determined 
with a biophotometer (Eppendorf, Hamburg, Germany)  
 
2.2.5.2 Reverse transcriptase (RT) reaction 
The ingredients for cDNA synthesis are illustrated in the table (Table 2.2).To this 
mixture 1 µg of RNA was then added with a maximum volume of 10µl. The reaction 
was then performed in the thermocycler (TGradient Thermocycler, Biometra, 
Göttingen, Germany) at 25 °C for 10 minutes, 37°C for 2 hours and 85°C for 5 minutes.  
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     Table 2.2 Ingredients of the reverse transcriptase reaction. 
 
2.2.5.3 Real-time PCR (qPCR) 
The real time polymerase chain reaction was executed utilizing Platinum® SYBR 
Green qPCR Super Mix (Invitrogen, Karlsruhe, Germany). The primers used in qPCR 
experiments are listed in the following table (Table 2.3).       
   
a) 
Tm, Melting temperature;
 b) 
nt, nucleotides 
c)
 F, forward; 
d)
 R, reverse 
  Table 2.3 Sequences of the primers used in the study. 
In table 2.4 all components of the reaction are represented. The ingredients were 
pipetted into a microtitre plate (Thermo-Fast 96 PCR Detection Plate, ABGene 
ThermoFisher Scientific) and the volume of 1 µl of cDNA was added. Subsequently, 
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the plate was sealed with a foil (Absolute Q-PCR Seal, ABGene- Thermo Fisher 
Scientific) and the reaction was performed by the StepOnePlus™ Real time PCR 
System (Life Technologies, Carlsbad, CA). 
 
  
     Table 2.4 Ingredients of the qPCR reaction.  
 
 
The cycling conditions were comprised of initial 10 min at 95°C, followed by 40 cycles 
of the following temperature-time profile: 95°C for 15 seconds and 1 minute at 60°C. 
The data were evaluated with StepOne™ Software (Life Technologies). Exclusion of 
non specific amplification or contamination was verified in melt curve analysis and 
agarose gel electrophoresis. All changes in the target gene mRNA levels are presented 
as delta ct (∆ct), which was calculated by subtracting the ct value of the target gene 
from the ct value of the reference gene. 
 
2.2.6 Statistics 
For statistic assessment of the results the GraphPad Prism software (GraphPad 
Software,Inc., San Diego, CA) was used. All data of patient and animal experiments 
are presented in form of box-whisker-plots. The upper whiskers indicate the maximal, 
the lower the minimal value, while the box constitutes the interquartile range. The 
median value is marked as a horizontal line within the box. In the experiments 
comparing two different groups, the statistic significance was determined by means of 
the Mann-Whitney-U test. In the case of three groups, ANOVA was utilized, followed by 
Turkey´s post noc test. The p value less than 0.05 was considered as statistically 
significant.
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3.  Results 
3.1  Contact activation factors are elevated in BALF and lung 
 homogenate of ARDS patients 
In order to investigate the characteristics of contact activation proteins in the 
pathogenesis of ARDS, their occurrence in lungs of affected patients was determined. 
As illustrated in Figure 4.1 Western blot analysis revealed increased protein levels of 
FXII, FXI, HK and KLK in BALF of ARDS patients compared to the healthy control 
group. Remarkably, two signals appeared for FXII, one 80 kDa band representing the 
FXII zymogen and a 50 kDa band corresponding to the heavy chain of FXIIa, indicating 
that FXII conversion into activated FXII is taking place. The nonappearance of the light 
chain of FXII at 30 kDa is justified by the specific antibody targeting an epitope only 
presented on the heavy chain of FXII.  
 
 
 
Figure 4.1 Elevated levels of contact activation factors in BALF of ARDS patients.            
FXII, FXI, HK and KLK protein levels in BALF of ARDS patients in comparison to the healthy control group 
assessed by Western blot. Here, 8 out of 46 ARDS patients and 5 out of 20 healthy controls are 
demonstrated.  The different bands are labeled. HCh, heavy chain; LCh, light chain. Coomassie Brilliant 
Blue (CBB) was applied as loading control for visualization of total protein content.  
 
Concurrent with indication of FXII conversion, activation of KLK was implied, as 
virtually no inactive zymogen at 88 kDa was detectable, while a strong signal for 
cleaved KLK heavy chain was apparent at 52 kDa in the BALF of ARDS patients. 
Accordingly, KLK substrate HK was identified in its activated two chain form, 
represented by its heavy chain at 62 kDa and the light chain at 56 kDa. Similar 
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observations were made for FXI, which was represented in its cleaved two chain active 
form at 80 kDa.  
In line with the Western blot results, the quantification of FXII concentration assessed 
by ELISA showed a significantly higher amount of the protein in lavage specimens of 
ARDS patients. In the patients group the interquartile range of FXII level was found to 
extend from 140 to 390 ng/ml with a total average of  274 ng/ml. The determination of 
FXII in the control group however revealed a total average of 130 ng/ml with an 
interquartile range stretching from 55 to 195 ng/ml (Figure 4.2 A). Interestingly, no 
significant increased of the FXII level was observed in patients suffering from cardiac 
lung edema compared to the control group, excluding the possibility of the FXII 
increase being due to the mechanical ventilation. In respect of the two different 
etiopathogenic forms of ARDS, FXII concentration was observed to be at a similarly 
high level in direct as in indirect ARDS samples (Figure 4.2 B). Further distinction 
revealed a variation of the FXII concentration according to the temporal course of the 
disease. Within the first 24 hours of the diagnosis the amount of FXII is found to be 
increased, remaining high for four days and subsequently decreasing on day 6-8  to 
values comparable to those of the control group (Figure 4.2 C). In contrast to the 
observations made for BALF samples, the determination of FXII in blood plasma 
revealed decreased levels of the protein in ARDS patients compared to the healthy 
control group. Thus, in the specimens of the patients the FXII concentration showed a 
total average of 32 µg/ml with an interquartile range between 20 µg/ml to 47 µg/ml, 
whereas the healthy group showed significantly higher values with a total average of 53 
µg/ml and an interquartile range from 36 µg/ml to 68 µg/ml (Figure 4.2 D).     
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Figure 4.2 Increased levels of FXII in the BALF of ARDS patients.                   
(A) FXII levels were determined in BALF obtained from ARDS patients (n=46), patients with cardiogenic 
lung edema (CLE) (n=10) and healthy controls (n=20).  (B) Differentiation of FXII levels in BALF of direct 
(n=28) and indirect (n=18) ARDS patients, all versus healthy control group subjects. (C) FXII levels in 
BALF from patients in the course of ARDS on day 1 (n= 46) , day 3-4 (n= 28) and 6-8 (n=27) opposed to 
healthy controls. (D) Determination of FXII level in blood plasma of ARDS patients (n=26) in comparison 
with control group (n=19). All data assessed by ELISA.  **p < 0.01; ***p < 0.001; ns, non significant. 
 
 
 
Representing an indirect product of the FXII activation with a major involvement in 
inflammatory processes, BK was another component of interest for the investigation. 
Particularly the observation of elevated occurrence of cleaved HK in the immunoblot of 
the patients gave rise to the assumption of a correspondingly altered BK level.  
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Therefore determination of BK concentration in BALF was assessed by ELISA, 
showing significantly higher amounts of the protein in specimens of the patients group 
(Figure 4.3).  
 
A                   B 
               
      C 
 
 
Figure 4.3 BK is elevated in BALF of ARDS patients.                  
(A) Quantification of BK level determined in BALF specimens from ARDS patients (n= 46), patients with 
cardiogenic lung edema (n=10) and the healthy controls (n=20) assessed by ELISA. (B) Comparison of BK 
levels in BALF of ARDS patients of pulmonary (n=28) versus non pulmonary (n=18) source. (C) Analysis 
of the BK concentration in BALF obtained from ARDS patients at day 1 (n=46), day 3-4 (n=28) and day 6-8 
(n= 27) during the temporal progression of the disease. **p < 0.01, *** p < 0.001; ns, non significant.  
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While the BALF of ARDS patients contained an average concentration of 3.47 ng/ml 
BK with an interquartile range between 2.10 - 4.00 ng/ml, the average control group 
was stated at a significantly lower level of 0.45 ng/ml and an interquartile range of 0-
0.50 ng/ml. By contrast, in patients with a lung edema due to cardiac failure, no 
significant alteration of BK levels was detected in comparison to the healthy donors 
(Figure 4.3 A). In view of the etiopathologic differentiation, elevated BK levels were 
observed in direct as in indirect ARDS, showing no significant difference between the 
two groups (Figure 4.3 B). Analysis of the temporal evolvement reveals an initial high 
level on day 1 after the diagnosis, remaining elevated for eight days with declining 
tendency from day six on (Figure 4.3 C).   
Additional experiments were performed to examine the expression of intrinsic blood 
coagulation factors in human lung homogenate. Western blot analysis revealed a 
steady high protein level in ARDS affected lung tissue in comparison to the control 
group (Figure 4.4). With regard to the previous observations in BALF specimens; 
indicators of FXII conversion were equally present in the lung tissue.  
 
 
Figure 4.4 Altered expression of contact activation factors in ARDS lung tissue.        
Determination of protein level of FXII, FXI, HK and KLK in lung homogenate of ARDS patients and healthy 
controls. 5 out of 7 ARDS patients and 5 out of 6 controls are demonstrated. As a loading control β-actin 
was used. * unspecific band. 
          
 
 
 
 
Results 
 
- 35 - 
 
 
 
A                 B    
  
 C      D     
      
    E      F 
                      
   G 
        
Figure 4.5 Altered expression of contact activation factors in ARDS lung tissue     
Densitometry analysis of the immunoblot of Figure 4.4 for FXII zymogen (A) and FXIIa HCh (B), FXIa (C), 
HKa HCh (D) and HKa LCh(E), PKLK (F) and KLK HCh (G). ARDS (n=7), Control (n=6). Rel., relative; 
HCh, heavy chain; LCh, light chain. *p < 0.05 
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Quantification of the Western blot results performed by densitometry analysis 
confirmed higher protein levels in ARDS lung tissue. Accordingly the relative protein 
expression of FXII was detected in ARDS lungs to shift between 0.33 - 0.56 with an 
average of 0.45, whereas the control group showed FXII rates of 0.03 - 0.57 with an 
average of 0.21. The protein expression of FXIIa heavy chain revealed an average of 
0.12, in comparison of 0.03 to the control group.  The relative protein rate of FXIa in 
ARDS lungs was detected to vary among 0.04 and 0.45 with an average of 0.38, while   
in control lungs FXIa protein expression was determined at 0.012 to 0.34 with an 
average rate of 0.17. The expression of HKa heavy chain was detected in ARDS lungs 
to shift from 1.12 to 0.39, in the control group from 0.03 to 0.9.  HKa light chain was 
found at a significantly higher protein rate in ARDS lungs compared to healthy controls, 
with rates of 1.2 to 0.02, whereas in lung tissue of the control group the protein 
expression shifted from 0.01 to 0.03.  Minor variation in protein expression was 
determined for PKLK, with an average in ARDS patients of 0.15 and in the control 
group of 0.08. For KLK protein expression no difference was detectable in the ARDS 
group compared to the healthy controls.  
In summary, FXII, FXIIa, FXI and HKa were found in higher protein rates in ARDS 
lungs compared to the control group, however not reaching statistical significance 
(Figure 4.5 A-G).  
 
3.2  FXII expression is increased in blood cells of ARDS patients   
The role of hepatocytes as main producer of FXII is generally acknowledged, however 
evidence of extrahepatic synthesis has been obtained in previous research (183). 
Consequently, the interest arose whether within lung injury supplementary cells might 
play a role as a potential source of FXII protease. To this end, mRNA of FXII was 
evaluated in human lung homogenate and leukocytes by means of qPCR. Interestingly, 
the FXII expression was significantly higher in lung homogenate of ARDS patients in 
comparison to control subjects (Figure 4.6 A). Furthermore, in leukocytes isolated from 
the blood of healthy donors FXII mRNA was not detectable, whereas in leukocytes of 
ARDS patients FXII was distinctly expressed (Figure 4.6 B).  
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Figure 4.6 Expression of FXII is altered in lung tissue and blood cells of ARDS patients.      
Expression of FXII in (A) lung homogenates obtained from control subjects (n=5) and ARDS (n=5) patients 
and in (B) leucocytes of healthy donors (n=10) and ARDS patients (n=6) assessed by qPCR. All data are 
expressed as ∆ct using β-actin as a reference gene. *p < 0.05; N.D., non-detectable. 
 
 
 
3.3  The protein level of FXII and BK is elevated in lungs of bleomycin-
 treated mice 
To ascertain whether comparable conditions apply for the animal model of lung injury, 
Western blots of FXII were performed for BALF of bleomycin-treated mice. To 
reproduce the feature of human lung injury most realistically, the lavage samples used 
were of mice 5 days after bleomycin application, thus representing the acute 
inflammatory response. FXII concentrations were found to be significantly elevated in 
murine BALF of bleomycin challenged mice compared to the saline treated mice in 
Western blot analysis (Figure 4.7). 
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Figure 4.7 Levels of FXII and FXIIa is elevated in BALF of bleomycin treated mice.                      
Levels of FXII and FXIIa in BALF of mice treated with either saline or bleomycin 5 days post application. 
Representative Western blot is demonstrated. Here 4 Saline and 5 out of 9 bleomycin challenged mice are 
shown. 
 
 
FXII conversion in BALF of bleomycin treated mice was indicated by a signal for FXII 
zymogen with concurrent appearance of FXII heavy, leading to the assumption of 
ongoing FXII activation. Moreover, detection of FXII was executed for murine lung 
tissue samples at day 5 and day 10 post bleomycin application. Illustrated in Figure 
4.8, a strong signal was observed in bleomycin challenged murine lung homogenate, 
whereas saline treated mice showed markedly lower expression of FXII. Quantification 
of the protein band by densitometry analysis confirmed significantly higher FXII/FXIIa 
levels in samples of bleomycin injured lungs (Figure 4.8 B, C). In view of the temporal 
course, FXII concentration is found to be higher at day 5 post bleomycin instillation with 
subsequent reduction.  
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Figure 4.8 Increased protein level of FXII/FXIIa in lung homogenate of mice at day 5 and day 10 
after bleomycin instillation.                   
(A) Levels of FXII/XIIa in lung tissue of mice treated with bleomycin on day 5 and day 10 post application. 
Representative Western blot is demonstrated. As a loading control β-actin was applied. Quantification of 
Western blot results for (B) FXII zymogen and (C) FXIIa HCh was assessed by densitometric analysis. 
Saline (n=5), bleomycin day 5 (n=9) and bleomycin day 10 (n=9) mice are shown. HCh, heavy chain; Rel., 
relative. *p < 0.05, **p < 0.01.  
 
 
 
Determination of BK protein level in murine lungs was further assessed by ELISA, 
revealing significantly higher BK levels in the BALF of bleomycin injured lungs. 
Whereas the average concentration of BK in BALF of the saline treated control group 
was 15.27 ng/ml, the mean value of BK after bleomycin administration was 43.3 ng/ml 
at day 5 and 34.94 ng/ml at day 10 post application.    
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Figure 4.9 Increased level of BK in BALF of mice at day 5 and day 10 after bleomycin application   
Determination of BK level in BALF of mice at day 5 (n=9) and day 10 (n=9) after bleomycin application 
compared to saline control group (n=5)  assessed by ELISA. **p < 0.01; ns, non significant               
 
 
3.4  C1 esterase inhibitor (C1 INH) decreases inflammatory response in 
 bleomycin challenged murine lungs 
 
3.4.1  C1 INH alleviates the inflammatory response induced by bleomycin 
 application 
To further define the role of contact activation, effects of its inhibition on acute lung 
injury were examined in murine lungs. The animals were divided into three different 
experimental groups. While the first group received saline application, the second and 
third group were challenged with bleomycin. Subsequently, C1 INH, acknowledged to 
be a main inhibitor of the contact system, was administered to the former (Saline+C1 
INH) and the second group (Bleo+C1 INH), whereas the third group received a vehicle 
only (Bleo+Vehicle). All animals of the investigation were sacrified on day 5 after 
bleomycin or saline application, respectively. 
Morphological evaluation of the lung tissue was then performed. In the lungs of saline 
treated mice that received C1 IHN no alterations of the lung tissue were found and the 
physiological alveolar architecture was maintained (Figure 4.10). In the bleomycin 
group, the mice with vehicle administration only showed the typical feature of 
bleomycin induced lung injury including infiltration of leukocytes into the interstitial 
space and swelling of the alveolar wall. By contrast, in lungs of mice treated with C1 
INH a striking diminution of the bleomycin caused inflammation was observed. 
Accordingly, a considerable reduction of inflammatory cells in the interstitial and 
alveolar compartment was apparent (Figure 4.10) 
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Figure 4.10 Application of C1 INH reduces the inflammatory response in bleomycin treated mice. 
Hematoxylin-eosin stained paraffin embedded lungs obtained from animals either treated with saline+C1 
INH, bleomycin+vehicle or bleomycin+C1 INH, n=5-8/group. Magnification 20x. 
 
 
These observations were confirmed by the analysis of the BALF, revealing an increase 
of leukocytes in specimen of mice after bleomycin challenge and a significant lower 
number of leukocytes after C1 INH administration compared to those after vehicle 
treatment (Figure 4.11 A).  
Accordingly, neutrophils, a subgroup of leukocytes known to be of pivotal importance in 
the pathogenesis of ARDS were significantly reduced in animals receiving C1 INH 
(Figure 4.11 B),  the relative proportion of neutrophils among total leukocytes, however, 
remained the same (Figure 4.11 C).  
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Figure 4.11 Application of C1 INH reduces number of inflammatory cells in bleomycin challenged 
mice. (A-C) Quantification of leukocytes and neutrophils in BALF of bleomycin challenged mice assessed 
by flow cytometry. n=5-8/group; *p < 0.05, **p < 0.01; ***p < 0.001; ns, non significant. 
 
 
Evaluation of the wet/dry ratio as indicator for edema formation in the lungs revealed a 
significantly higher rate after bleomycin application compared to the saline control 
group. The edema was found to be significantly reduced after C1 INH administration 
(Figure 4.12.) 
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Figure 4.12 Decrease of edema formation after C1 INH administration in bleomycin treated mice. 
Determination of the wet/dry ratio in the lungs of either saline control group or bleomycin challenged lungs 
with vehicle or C1 INH application;  n=5-8/group;  *p< 0.05, ***p< 0.001.   
             
   
3.4.2  Expression of proinflammatory mediators in bleomycin injured lungs is 
 reduced after C1 INH application 
To further scrutinize the putative effect of C1 INH administration on bleomycin injured 
lungs, mediators known to be involved in the inflammatory response were examined. 
The macrophage inflammatory protein 2 (MPI-2/CXCL2) is known to be a crucial 
participant in neutrophil recruitment in the course of ARDS. Determination of MIP-2 
mRNA expression in lung homogenate revealed a remarkable increase of MIP-2 in 
bleomycin injured lungs with vehicle administration and a significantly decreased 
expression in mice treated with C1 INH (Figure 4.13 A). TNF-α, known to be a pro-
inflammatory mediator and contributor to fibrotic alterations in the lung, was found to be 
significantly higher expressed in vehicle treated bleomycin mice, whereas C1 INH 
application induced a significant decline of the cytokine (Figure 4.13 B). By contrast, C1 
INH failed to exhibit an impact on the expression of IL-1β. Thus, IL-1β expression was 
significantly increased in all bleomycin treated mice, independent of whether they had 
subsequently received C1 INH or vehicle only (Figure 4.13 C). 
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Figure 4.13 Expression of MIP-2 and TNF-α is reduced after C1 INH administration in bleomycin 
challenged mice.            
Expression of MIP-2 (A), TNF- α (B) and IL-1β (C) in lung homogenates of mice post saline instillation with 
C1 INH application (saline+C1 INH), in bleomycin mice with vehicle administration (bleomycin+vehicle) 
and bleomycin mice with C1 INH application (bleomycin+C1 INH) assessed by qPCR. Data are expressed 
as ∆ct using β-actin as a reference gene, n=5-8/group. *p< 0.05, **p< 0.01; ns, non significant. 
    
 
 
 
 
 
 
 
Results 
 
- 45 - 
 
3.4.3  C1 INH administration has no impact on coagulation in bleomycin 
 challenged mice 
It is well established that alveolar coagulation is subject to alterations in lungs of ARDS 
patients; therefore it was of particular interest to investigate possible effects of C1-INH 
administration on the hemostatic status. For this reason, measurement of the clotting 
time was performed for a saline control group and bleomycin challenged mice, the 
latter either treated with C1 INH or vehicle only. The evaluation revealed a highly 
significant acceleration of the clotting time in bleomycin challenged mice compared to 
the saline control group. Whereas the clotting time of the saline treated mice was 
observed to vary between 580 to 800 seconds, a striking diminution with an average of 
100 seconds was noted in mice after bleomycin application. This observation is 
consistent with the current knowledge of a predominantly procoagulant setting during 
lung injury. Remarkably, the clotting time was not decelerated after C1 INH 
administration, thus no difference to the vehicle treated mice was observable (Figure 
4.14 A).  
Representing the final product of coagulation activity, fibrinogen was another object of 
the investigation. Determination of fibrin(ogen) in murine lung samples assessed by 
Western blot analysis revealed an explicit increase of the protein in samples of animals 
challenged with bleomycin. No difference was noted in the experimental groups, 
showing a comparably high amount of fibrinogen independent of whether they were 
treated with C1 INH or vehicle only (Figure 4.14 B). Further examination included 
determination of D-dimer, the decomposition product of cross-linked fibrin and 
therefore marker of fibrin formation and dissolution. The amount of D-dimer in the 
plasma of mice with lung injury was detected to be significantly higher than in the 
control group. No significant effects could be found in the experimental group after C1 
INH treatment (Figure 4.14 C). In conclusion, after bleomycin application the mice 
developed the known features of acute lung injury with an increase of procoagulant 
activity, represented by the accelerated clotting time and increase of fibrin and fibrin 
degradation products. No significant distinction could be identified in the experimental 
group between animals which had received C1 INH treatment and those after vehicle 
application. Consequently, the results demonstrate the administration of C1 INH as 
having no effect on the hemostatic state. 
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Figure 4.14 C1 INH application has no impact on altered coagulation in bleomycin induced lung 
injury.             
(A) Procoagulant activity of BALF from animals subjected to saline or bleomycin and then treated with 
either C1 INH or vehicle.  (B) Fibrin(ogen) deposition in the lungs of mice post saline instillation and C1 
INH administration (Saline+C1 INH) and bleomycin mice treated either with C1 INH (bleomycin+C1 INH) or 
vehicle only (bleomycin+vehicle). Representative Western blot is shown.  (C) Quantification of D-dimer 
antigen level in BALF samples from each group, Saline+C1 INH, bleomycin+C1 INH and bleomycin + 
vehicle. n= 5-8/group. **p<0.01; ns, non significant.                                                                                       
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4.  Discussion 
4.1  The contact activation factors are increased in ARDS lungs  
The altered alveolar hemostatic state is a condition generally recognized in 
inflammatory lung diseases and it has been an object of research to clarify the role of 
coagulation factors within inflammatory and fibrotic processes in this context. Extrinsic 
proteases of blood coagulation are found to be increased in the lungs of ARDS patients 
(162) and have been identified to not only promote fibrin formation via the coagulation 
cascade, but to additionally contain pro-inflammatory properties by inducing the 
expression of cytokines (168, 173). Furthermore, pro-fibrotic effects are attributed to 
the FXa protease, attaching further importance to the components of the clotting 
cascade in view of fibrotic remodeling of the lung (186).  The present study examines 
the impact of the contact system on the pathogenesis of acute lung injury, particularly 
ARDS, exhibiting elevated protein levels of FXII, FXI, KLK and HK in BALF and lung 
tissue of ARDS patients. This surge of intrinsic blood coagulation factors in BALF and 
lung tissue is presumably primarily due to the impaired integrity of the alveolar barrier 
generally found in the lung of ARDS patients, leading to influx and accumulation of 
proteins in the alveolar and interstitial compartment (132, 187). However, it seems 
worthwhile considering whether besides the alveolar leakage; intrapulmonary 
generation may be another cause for the accrued amount of intrinsic factors at the site 
of lung injury. In this context, results of the current study draw particular attention to 
inflammatory cells as putative source of FXII, revealing FXII expression in leukocytes of 
ARDS patients whereas in the white blood cells of healthy subjects FXII was not 
detectable. Thus, the inflammatory cells may represent an extrahepatic origin of FXII 
production and leukocytes invading into the pulmonary tissue within the inflammation 
may contribute to elevated FXII levels in the lung tissue of ARDS patients. Moreover, 
the possibility of FXII generation by resident lung cells can neither be excluded from 
consideration. Evidence of intrapulmonary FXII production has been obtained in lungs 
of IPF patients as under fibrotic conditions human lung fibroblast have been detected to 
express FXII (182). Whether local synthesis by lung fibroblasts or epithelial alveolar 
cells may play a role in inflammatory lung diseases remains object of future studies. 
 
Another important aspect of this study was the provision of evidence of intrinsic 
pathway activity in the lungs of ARDS patients. Accordingly, conversion of FXII into its 
activated form and complete activation of its substrates was detected in the presented 
Western blot results. However, it should not be neglected that FXII independent 
pathways have been described for KLK and FXI cleavage respectively, which 
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consequently also need to be taken into consideration as a potential mechanism for 
their activation in affected lungs (188, 189). Within the course of the disease a higher 
rate of FXII conversion is suspected to eventuate with local accumulation in the lung. 
Amplified degradation of the protein due to the boosted activation leads then to 
extended consumption of FXII, which is reflected in the decline of the protease in the 
plasma. This is particularly remarkable, as in septic patients decreased FXII plasma 
levels have been noted to signify an unfavorable prognosis (190). Consequently, the 
question arises of how FXII activation may occur during lung injury. A variety of 
approaches have been pursued in the past years concerning the mechanism of FXII 
activation under physiological conditions. In view of potential pro-inflammatory features 
of the protease, particular interest has been drawn to studies indicating that the 
activation of contact factors might occur on the surface of neutrophils. In line with this 
approach, previous investigations demonstrated  binding of purified FXII and HK, 
respectively, to the surface of neutrophils, notably in immediate vicinity to each other, 
resulting in an increase of KLK activity (191). In this way, the activation of the contact 
system proteases in acute lung injury might occur on infiltrating neutrophils at the site 
of inflammation.  Additionally, platelets have been suspected to be associated with the 
initiation of the contact activation system (44). A possible mechanism seems to include 
the release of inorganic polyphosphate (PolyP) from thrombocytes, which bind to FXII 
and thereby trigger its activation and subsequent BK generation (45). Another potential 
activator of FXII further represents extracellular RNA, contingently originating from 
dying cells within tissue damage or disintegrating pathogens (42). In ARDS of 
infectious origin bacterial mediated contact activation may further play an essential 
role. Accordingly, assembly and activation of the proteases belonging to the contact 
system have been observed on the surface of Streptococcus pyrogens, 
Staphylococcus aureus and Escherichia coli (192-194).  
 
The current results further revealed an independence of the FXII augmentation from 
the etiopathologic origin of the disease. Thus, no considerable difference was 
detectable whether ARDS was based on pulmonary or non pulmonary genesis. This 
observation coincides with the findings for extrinsic coagulation factors, showing 
equally elevated activity of tissue factor and FVII in direct as in indirect ARDS (162).  
The differentiated analysis of the temporal course revealed an instant increase of FXII 
within the first 24 hours of the diagnosis. The protein level remains high for four days 
and then declines to rates comparable to the values of the healthy control group.                                                                                                                   
In view of a potential role of contact system activation in ARDS, this discovery draws 
particular attention to the early stage of the disease, which is known to be 
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characterized by inflammatory alteration of the lung tissue with a surge of cytokines 
and infiltration of leukocytes (187). In this context it is noteworthy that pro-inflammatory 
attributes of contact activation proteases in general and in the lung in particular have 
been addressed in previous research (115, 184). Thus, ample evidence has been 
provided that KLK and FXIIa induce aggregation of neutrophils and stimulate the 
release of neutrophil derived elastase in vitro (114, 117, 119). Accordingly, in KLK and 
FXII deficient plasma a remarkable decline of neutrophil elastase liberation has been 
described (119).  Therefore it is of special interest, that in BALF and plasma of ARDS 
patients the level of the neutrophil elastase has been detected to be significantly 
elevated (195, 196). Containing destructive effects on the endothelium of the lung, the 
neutrophil elastase crucially contributes to the alteration of the alveolar membrane, 
leading to a protein rich edema and extravasation of inflammatory mediators into the 
alveolar and interstitial space (197). The molecular mechanism of the interaction 
between the contact system factors and the leukocytes engendering the release of 
neutrophil elastase remains unknown. Earlier investigations suggest an involvement of 
the catalytic domain as well as the heavy chain, since β-FXIIa failed to unfold its impact 
on the immune cells (117), possibly due its inability to bind to the cells. Of further 
particular interest in this regard is the present finding of elevated amounts of BK in 
BALF of ARDS patients. Given the manifested role of the nanopeptide in inflammatory 
processes (88, 89, 100, 102), the suggestion arises as to whether a significant 
participation in the pathogenesis of acute lung injury might be assigned to BK. (101) Up 
to date, various pro-inflammatory effects of BK in the lung have been explored as 
inducing the release of cytokines with neutrophil chemotactic activity, particularly IL-8, 
in pulmonary epithelial cells  (101, 102). Aside from FXII and KLK, BK represents 
another component, demonstrated to induce the release of neutrophil elastase and 
thereby promoting the leakage of the alveolar membrane (198). In addition to the 
inflammatory attributes of the contact system factors, a pro-fibrotic contribution in 
ARDS might also be worthwhile considering. According to the present state of 
knowledge, fibrotic alterations in affected lungs appear within the early phase of the 
disease (153, 199), thus concurrent with the elevated FXII levels observed in the 
present study. In a former animal study, limited fibrotic manifestation in FXII (-/-) mice 
after bleomycin challenge has been demonstrated (182), implying pro-fibrotic features 
of the serine protease. A fibrotic capability of FXII might be attributed to its activity as a 
component of blood coagulation, initiating via proteolytical cleavage the intrinsic 
coagulation cascade and thereby promoting fibrin generation. This is contradicted, 
however, by the restricted significance of the intrinsic pathway in hemostasis in vivo. 
Furthermore, despite reduced fibrosis in FXII (-/-) mice, fibrin generation was equally 
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detected in the experimental and control group, thus the involvement of the contact 
system protease in fibro-proliferative alteration seems to be found beyond its 
procoagulative action (182). Promising approaches in this context are attributed to the 
mitogenic features of FXII. Accordingly, FXII has been identified to contain mitogenic 
activity on hepatocytes, endothelial cells, alveolar cells and aortic smooth muscle cells 
(22, 33), most likely involving the EGF-like domains of the protease.  In line with these 
findings, a FXII mediated proliferative effect under participation of u-PAR has also been 
observed in murine lung fibroblasts (182). Besides, pro-fibrotic attributes may also be 
assigned to BK as in lung fibroblasts the peptide has been described to provoke 
proliferation, increased expression of α-smooth muscle actin (α-SMA) and enhanced 
collagen synthesis (200). Thus, BK possibly represents another component involved in 
the fibrotic response within ARDS. 
 
The observations in ARDS lungs of the current study corresponded to the findings in 
the animal model of lung injury. To reproduce the pattern of lung injury, mice were 
intratracheal bleomycin challenged. Evoking similar pathological changes in murine 
lungs by inducing the release of cytokines, infiltration of neutrophils and formation of a 
pulmonary edema, bleomycin application is a common method to provoke the 
pathological pattern observed in the lungs of ARDS patients (201). Besides, another 
analogy with ARDS is found as the bleomycin induced neutrophilic alveolitis merges 
into a reversible fibrotic alteration. The conditions 5-10 days post bleomycin application 
particularly meet the criteria of the acute inflammatory early fibrotic phase of lung injury 
(201). Therefore, the experimental animals used were sacrified on day 5 or 10 after 
intratracheal bleomycin instillation. However, the pathological processes within acute 
lung injury are multifarious and may not be fully reproduced in animal models, thus 
there are naturally limitations to these experiments. This study revealed an elevation of 
the FXII level in BALF of mice after bleomycin challenge with indicators for FXII 
conversion, leading to assume an ongoing activity of the contact system. Significantly 
increased levels of FXII zymogen and FXIIa were further detected in murine lung 
homogenate. The temporal comparison showed the protease at a higher level on day 5 
then on day 10. These observations are in line with the findings for ARDS lungs, 
revealing the FXII concentration to be initially at its highest and then to decline, 
emphasizing the particular involvement of contact activation within the early events of 
lung injury.  
As there are few measures identified to be of therapeutic benefit in ARDS, it is crucially 
important for future approaches to gain additional knowledge of the mediators involved 
in the pathological process. The current finding of elevated and activated contact 
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activation proteases in ARDS lungs with an elevated amount of the downstream 
product BK underscores the hypothesis of a contributive role of these factors within the 
progression of the disease. Not interfering with hemostasis, the inhibition of contact 
activation may represent an attractive therapeutic option. In the future, further research 
is required to focus on revealing more details of the pathological circumstances leading 
to pulmonary accumulation of the proteases and to identify the molecular processes 
contact activation may actuate within the development of ARDS. 
 
 
4.2  C1 INH administration moderates the inflammatory response in acute 
 lung injury 
Another pivotal discovery of this study was the recognition of a mitigating effect of C1 
INH on the inflammatory processes in bleomycin induced lung injury. This favorable 
impact includes a regression of the alveolitis with a marked reduction of inflammatory 
cells, especially neutrophils, just as a decline of the pulmonary edema. Remarkably 
both pulmonary edema formation as excessive neutrophil infiltration with subsequent 
degranulation, are key features of ARDS. Here the curiosity arises to determine the 
components involved in this protective effect of C1 INH, drawing paramount interest to 
the substrates possessing pro-inflammatory attributes. FXII, KLK and complement 
factor C1 are acknowledged to be inhibited by C1 INH (48-51). The inhibition of KLK 
further restricts the generation of BK, equally representing a mediator of inflammation. 
It is noteworthy that the complement system as well as the contact activation system 
are found activated in lung injury (202-204), thus the inhibition of either system might 
cause the beneficial effects of C1 INH administration.  
 
In research to date, mounting evidence of an advantageous impact of C1 INH 
administration in inflammatory diseases has been gained. Accordingly, a beneficial 
effect of the inhibitor application has been observed in an in vivo study on septic 
patients, revealing a decline of PMN activation after C1 INH administration 
accompanied by a reduced expression of disease-relevant cytokines (205). Besides, 
the referenced report accentuates the significance of the complement system, as C1 
INH substitution attenuated the activation of the classic pathway of complement, 
whereas no such effect was witnessed for FXII or KLK (205).  A preventive impact on 
the pulmonary function was further demonstrated in endotoxin challenged animal 
lungs, significantly ameliorating the PaO2 after C1 INH administration. The authors of 
the study suggest the beneficial effect to be mainly traced back to the inhibition of 
contact system factors (203). In line with this assumption, a reduced inflammatory 
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response was observed in experiments on septic baboons after C1 INH treatment with 
concomitantly decreased activity of contact system proteases (206). There are different 
conceivable scenarios of how contact system activation might participate in the 
pathogenesis of acute lung injury. Firstly, as pointed out above, contact system factors 
induce the aggregation of neutrophils and the release of the neutrophil elastase, an 
enzyme essentially contributing to the destruction of the alveolar membrane. 
Additionally the neutrophil elastase has been described to inactivate C1 INH under 
generation of cleaved C1 INH which lacks the ability to inhibiting plasma proteases. It 
may be therefore speculated that FXII induced release of the neutrophil elastase leads 
to enhanced C1 INH inactivation, which putatively may cause unrestricted activation of 
the contact and the complement activation system. Interestingly, in septic patients the 
level of cleaved, inactivated C1 INH is described to be elevated and to correlate with 
the clinical outcome (207). Similar conditions seem conceivable for ARDS and 
insufficient inhibition of the contact and complement activation system might reinforce 
the inflammatory response. Besides the neutrophil elastase, other tissue destroying 
components may be released due to contact system triggered neutrophil degranulation. 
Increased endothelial permeability in the lung may be augmented by HK derived-BK 
generation (90). As FXII, KLK and HK have been localized on endothelial cells, the 
alveolar endothelium might represent a potential site of activation of the contact system 
proteases where liberation of BK occurs. Released BK may effectuate in paracrine 
manner the increase of alveolar permeability, thus exacerbating the influx of protein 
rich fluids into the alveolar space.         
 
Previous investigations on the impact of C1 INH in septic baboons have revealed a 
decline of the cytokines IL-6, IL-8, Il-10 and TNF-α after the administration of the 
inhibitor, an effect suspected by the authors to be attributable to the inhibition of the 
contact activation system (206). Supporting this assumption, inhibition of FXII by 
monoclonal antibody C6B7 in baboons similarly revealed a decrease of IL-6 release 
during sepsis (118). In consistency with this observation, the present study 
demonstrated a decrease of the pro-inflammatory mediators MIP-2 and TNF-α after C1 
INH administration in bleomycin induced lung injury (206), whereas the expression of 
IL-1β remained unaffected. Finally, the activities of contact activation factors towards 
the complement system remain to be considered. Previous studies demonstrated that 
the first component of the complement system may also be activated by β-FXII, thus 
linking the pathways of the complement system and the contact activation cascade 
together (25, 26). The C1 of the complement represents the initiating component of the 
classic pathway, through proteolytic processing leading to the release of C5a, an 
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acknowledged chemo-attractant. C5a is recognized to bind to endothelial cells, induce 
neutrophil capture and increase vascular permeability under hypoxic conditions (208). 
The complement system as the central target of endogenous C1 IHN administration 
has been the focus in previous studies with controversial results. In septic patients, C1 
IHN substitution was demonstrated to lead to inhibition of the complement system and 
concurrent decline of neutrophil degranulation (205). However, in bacterial induced 
lung injury in an animal model, the administration of the inhibitor failed to prevent 
complement activation (202). Similarly, an insufficient inhibition of the complement 
system via C1 IHN administration has also been described for septic baboons (206). A 
most likely explanation for this may be found in the fact that the C1 INH interferes at an 
early level of the classic pathway of the complement system, without affecting the 
alternative cascade or other proteolytic processes leading to generation of the 
downstream complement products. Therefore, it is of no surprise, that C5a was found 
to be barely lowered after C1 INH administration (206). Based on these observations, it 
seems reasonable to presume that the complement system solely is insufficient to 
induce severe lung injury, as found in ARDS lungs. Instead, it seems more reasonable 
to conclude, that both systems, contact system activation in concert with the 
complement pathway precipitate the infiltration of neutrophils into the lung and 
concurrent edema formation. Summarily, the present results sustain the critical role of 
the contact system without dismissing an additional participation of the complement 
pathway.   
The imbalanced hemostatic state as generally found in inflammatory lung diseases was 
equally observed in the bleomycin-injured lungs. Accordingly, the clotting time was 
accelerated and D-dimer as indicator of boosted coagulation activity was significantly 
higher after bleomycin application. C1 INH substitution exhibited no impact on this 
procoagulative state, underlining the strongly limited significance of FXII in blood 
clotting. Determination of fibrin deposits revealed to be increased after bleomycin 
challenge. In line with previous investigations, the fibrin accumulation remained 
unaffected from C1 INH triggered-FXII blockage (194). These results indicate that the 
role of contact system within the pathogenesis of lung injury does not include an impact 
on the fibrin generation. Similar observations have been made in murine lungs with 
bleomycin induced fibrosis. Despite a significantly lower extent of fibrotic alteration in 
the lung of FXII (-/-) mice compared to the WT mice, no difference in fibrin generation 
was detectable between both groups (182).  
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The limitation of the investigation at hand is evidently based on the extended inhibiting 
activities of C1 INH, thus the present results do not exclude that the anti-inflammatory 
effect may be due to inhibition of factors other than the contact system proteases.  
 
Furthermore, the protection from lung injury might also be directly mediated by C1 INH 
itself, as evidence of anti-inflammatory activities independent of its function as protease 
inhibitor has been provided. Thus, C1 INH at plasma concentrations generally found in 
inflammation is observed to directly interfere with leukocyte extravasation (127).  By 
binding to P- and E- selectin adhesion molecules, C1 INH has been demonstrated to 
restrict leukocyte adhesion to endothelial cells in both in vitro and in vivo experiments 
(126, 127). Furthermore, in animal models of sepsis and endotoxin shock, C1 INH 
attaches directly to the bacterial lipopolysaccharids (LPS) and thereby inhibits LPS 
induced activation of macrophages and suppresses TNF-α synthesis (209). With 
regard to the results of the present study, the beneficial effect of C1 INH application in 
lung injury might be precipitated by direct C1 INH activity with the alveolar epithelial 
cells. It might therefore be of interest for future studies to examine whether the 
protective impact in lung injury is also observed when C1 INH is applied in its cleaved, 
inactivated form. 
Further research is also required to prove the explicit involvement of the contact 
activation system. Thus, a subject for prospective investigation might be the 
assessment of contact system activity after C1 INH substitution in bleomycin-injured 
lungs. A conceivable approach may further be the examination of a potential protection 
of FXII (-/-) mice from inflammatory alteration of the lung. Following the same reasoning, 
investigations on BK receptor (-/-) mice may elucidate the particular involvement of the 
peptide in lung injury.  An additional restriction of C1 INH may be due to its inability to 
inhibited surface bound contact proteases. Pursuing the idea of alveolar endothelial 
attached contact activation with local synthesis of BK, C1 INH administration may not 
achieve complete inhibition of the proteases. Another approach might therefore be to 
make use of a different inhibitor which also accesses to cell surface bound FXII, for 
instance the monoclonal Ab to FXII (C6B7) (194).  
 
However, despite the stated limitations, the significance of C1 INH as a main inhibitor 
of the contact, kallikrein-kinin and complement system is up to date undisputed, 
justifying that the inhibitor was chosen in the presented experiments. The anti-
inflammatory effect of C1 INH is substantiated by the current results, leading to the 
conclusion that the inhibitor might represent an effective way to interfere with contact 
activation triggered impairment of the lung. C1 INH for therapeutic application has 
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already been established in the treatment of hereditary angioedema with very few side 
effects; here an extended role of C1 INH as potential future medication in inflammatory 
lung diseases finds support.  
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5.  Conclusion 
In the past the biological relevance of the intrinsic proteases had been put to question, 
based on their dispensability in blood coagulation in vivo. Presently, the interest has 
been revived by the discovery of proinflammatory attributes of individual factors. This 
supplement role as intermediary in inflammation particular includes the FXII- and KLK- 
triggered induction of neutrophil aggregation and degranulation as well as the release 
of different cytokines. Of particular significance is further the KLK initiated liberation of 
BK. Being a well established mediator of vasodilatation and inflammatory processes, 
BK has been described to stimulate the release of various cytokines in lung fibroblasts 
and airway smooth muscle cells.  
In line with this recognition the results of the present study imply an involvement of the 
contact activation proteases in inflammatory lung diseases such as ARDS. In BALF 
and lung homogenate of ARDS patients the protein level of FXII, FXI, KLK and HK 
were elevated with indications of enhanced proteolytic activity of the contact system. 
The protein levels of FXII and BK were simultaneously raised in the early, inflammatory 
phase of ARDS and declined from day 6 onwards. The increase of both proteins was 
detected to be independent of the etiopathological origin and specific for ARDS as no 
increase of FXII and BK was apparent in BALF of patients with pulmonary edema 
based on cardiac failure. These findings were in accordance with the results of the 
animal model of lung injury, showing FXII and BK protein levels significantly elevated. 
In the qPCR analysis FXII was detected to be expressed by leukocytes of ARDS 
patients, revealing a potential extrahepatic source of the contact system initiating factor 
during lung injury.  
The administration of C1 INH prevented the inflammatory destruction of the alveolar 
tissue in bleomycin lungs. This beneficial effect of the inhibitor included a decline of 
immigrating immune cells, particularly of neutrophils and the decrease of the 
inflammatory cytokines TNF-α and MIP-2, both known to reinforce the inflammatory 
response in lung injury. Moreover, a significant regression of the alveolar edema was 
observed after C1 INH application. As expected the unbalanced hemostatic state 
remained unaffected by C1 INH treatment.  
In conclusion, the present data demonstrate an anti-inflammatory effect of C1 INH 
administration on lung injury and provid founded reason to suggest an involvement of 
the contact system proteases.   
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6.     Summary 
The pathological features of the acute respiratory distress syndrome (ARDS) are 
hallmarked by inflammatory processes in the lung with an impairment of the alveolar 
membrane precipitating the formation of a pulmonary edema and commonly 
accompanied by massive interstitial fibrin disposition. Despite the increasing 
knowledge of the disease, protective ventilation with a low tidal volume is the only 
therapeutic measure recognized to substantially reduce the mortality. Accordingly, over 
the past decades mortality has remained at a high level, emphasizing the necessity for 
further scientific research and analysis. Research up to date has substantiated the 
finding of an altered alveolar hemostatic state, accrediting a potential role in lung injury 
to the factors of blood coagulation. Thus, in the lungs of ARDS patients boosted activity 
of procoagulant proteases has been observed with contemporary restriction of the 
fibrinolytic system, resulting in amplified generation and interstitial accumulation of 
fibrin. Investigations performed heretofore focused particularly on the extrinsic factors 
of blood coagulation due to their established role as a source of fibrin. On the contrary, 
the intrinsic proteases are acknowledged to be of limited importance for blood clotting 
in vivo however, accumulating evidence has been gained of an extended participation 
in fibrotic and inflammatory processes. The intrinsic pathway of blood coagulation is 
also referred to as the contact system and consists of the factor XII (FXII), factor XI 
(FXI), kallikrein (KLK) and high molecular weight kininogen (HK). 
C1 esterase inhibitor (C1 INH) represents not only the sole inhibitor of the classic 
pathway of complement activation but also the main inhibitor of the contact system, 
irreversibly inactivating FXII and KLK by complex formation. The anti-inflammatory 
attributes of C1 INH have been detected to extend beyond its activity as serine 
protease inhibitor, including also the prevention of leukocyte migration by directly 
interacting with endothelial cells. This study contemplates the involvement of the 
intrinsic factors of blood coagulation in lung injury with particular focus on FXII, the 
initiator of the intrinsic cascade. The investigation further aims at determining whether 
C1 INH application might display an effect on the course of the disease. Elevated 
levels of FXII, FXI, KLK and HK in the bronchoalveolar lavage fluids (BALF) and lung 
tissue of ARDS patients were observed with evidence of ongoing contact system 
activity. The investigation revealed an instant increase of FXII concomitant with the 
onset of the disease, leading to assume that the impact of the contact system is to be 
found within the early phase of the disease. In consistency with these results for ARDS 
patients were the observations made in the animal model of lung injury; here 
correspondingly increased FXII levels in BALF and lung homogenate became evident 
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after bleomycin application. As unrestrained activation and infiltration of neutrophils 
represents a central feature of ARDS, one might speculate that the mechanism of how 
contact system proteases may aggravate lung injury is possibly related to the ability of 
FXII and KLK to trigger neutrophil aggregation. Another decisive discovery of the 
investigation was the increased BK level in the BALF of ARDS patients and the mouse 
model of lung injury, presumably due to enhanced contact system activity. In addition 
to its proinflammatory attributes, BK can be assumed to contribute to lung injury by 
increasing the alveolar capillary permeability and thereby aggravating the pulmonary 
edema. The study further indicated that under pathological conditions, cells other than 
hepatocytes play a role in FXII generation as FXII mRNA was detected in leukocytes of 
ARDS patients. Of pivotal interest for future therapeutic approaches is the here 
presented recognition of a favorable effect of C1 INH administration in lung injury. 
Thus, C1 INH application was shown to attenuate the inflammatory process in 
pulmonary tissue of bleomycin injured lungs, significantly reducing the number of 
inflammatory cells, particularly neutrophils and inducing a regression of the alveolar 
edema. Furthermore, administration of the inhibitor was followed by a significant 
decrease of tumor necrosis factor- α (TNF-α) and macrophage inflammatory protein-2 
(MIP-2); both cytokines are well established as mediators of inflammation in lung injury.  
In summary, the present study provides reason to assume an implication of the contact 
system factors in the inflammatory process of the ARDS, possibly by promoting the 
release of cytokines causing neutrophil derived lung tissue destruction. Furthermore, a 
protective effect of C1 INH in lung injury is described, pointing towards the anti-
inflammatory properties of the serine protease inhibitor such as the inhibition of 
neutrophil recruitment to the sites of injury via binding of C1 INH to selectins. Therefore 
the investigation draws new attention to C1 INH as a potential future option in the 
therapy of inflammatory lung diseases such as ARDS.  
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7.  Zusammenfassung 
Der pathologische Prozess des acute respiratory distress syndrome (ARDS) ist 
gekennzeichnet durch eine entzündliche Veränderung der Lunge mit Beeinträchtigung 
der Alveolarmembran, in deren Folge es zur Ausbildung eines Lungenödems und 
massiver interstitieller Fibrinablagerung kommt. Trotz zunehmender Erkenntnisse über 
die Erkrankung bleibt die lungenprotektive Beatmung mit niedrigen Tidalvolumina die 
bis heute einzig anerkannte, therapeutisch wirksame Maßnahme. Gegenwärtig liegt die 
Mortalität des ARDS weiterhin auf einem hohen Niveau von bis zu 48%, woraus sich 
die dringende Notwendigkeit weiterer wissenschaftlicher Untersuchungen ergibt. Die 
Entdeckung eines veränderten alveolar-hämostatischen Status bei betroffenen 
Patienten wurde in verschiedenen Studien bestätigt und lässt einen möglichen Einfluss 
verschiedener Blutgerinnungsfaktoren auf die Lungenschädigung vermuten. In der 
bronchoalveolären Lavage (BALF) von ARDS Patienten ist die Gerinnungsaktivität 
erhöht mit gleichzeitiger Reduktion der Fibrinolyse, woraus eine verstärkte Produktion 
sowie interstitielle Ansammlung von Fibrin resultiert. Aufgrund ihrer etablierten Rolle in 
der Generierung von Fibrin konzentrierten sich bisherige Studien in diesem 
Zusammenhang insbesondere auf die Bedeutung extrinsischer Gerinnungsfaktoren. 
Die begrenzte Wirkung der Faktoren des intrinsischen Weges in der Blutgerinnung in 
vivo ist allgemein anerkannt, hingegen scheint ihre Beteiligung an verschiedenen 
entzündlichen und fibrotischen Prozessen von höherer Relevanz zu sein. Der 
intrinsische Weg der Blutgerinnung setzt sich zusammen aus den Faktoren XII (FXII), 
Faktor XI (FXI), Kallikrein (KLK) und high molecular weight kininogen (HK) und wird 
auch als Kontaktaktivierungssystem bezeichnet.  
Der C1 Esterase Inhibitor (C1 INH) ist ein Serinprotease-Inhibitor und in dieser 
Funktion nicht nur der einzige Inhibitor des klassischen Wegs des 
Komplementsystems, sondern auch Hauptinhibitor des intrinsischen Systems. Die anti-
entzündlichen Eigenschaften von C1 INH sind jedoch nicht allein auf seine Aktivität als 
Proteaseinhibitor begrenzt. Eine direkte Wechselwirkung von C1 INH mit 
Endothelialzellen wurde ebenfalls beschrieben, welche die Bindung von Leukozyten an 
das Endothel und somit die Diapedese verhindert.  
Gegenstand dieser Studie ist die Untersuchung einer potentiellen Beteiligung der 
Faktoren des Kontaktaktivierungssystems in der Pathogenese akuter 
Lungenschädigung. Hierbei liegt der Schwerpunkt der Experimente vorwiegend auf 
dem FXII, welcher als Initiator der Kaskade von besonderem Interesse ist. Ein weiterer 
Zusammenfassung 
 
- 60 - 
 
Fokus ist die Untersuchung eines möglichen Effekts von C1 INH auf den 
Krankheitsverlauf. In den Experimenten zeigte sich ein erhöhter Proteinlevel der 
intrinsischen Faktoren FXII, FXI, KLK und HK in der Lungenlavage sowie im 
Lungengewebe von ARDS Patienten. Außerdem ließen die Beobachtungen auf eine 
fortlaufende Aktivität des Kontaktaktiverungssystems schließen. Der Anstieg des FXII 
Levels zeigte sich hierbei unmittelbar mit dem Beginn der Erkrankung. Diese 
Beobachtung lässt vermuten, dass der Einfluss der intrinsischen Faktoren auf den 
pathologischen Verlauf insbesondere in der frühen Phase der Erkrankung zu finden ist.  
Übereinstimmend mit diesen Erkenntnissen waren auch die Ergebnisse der Versuche 
an Tiermodellen der akuten Lungenschädigung. Auch hier zeigte sich ein Anstieg des 
FXII Levels in BALF und im Lungenhomogenat nach Bleomycin Applikation. 
Angesichts der massiven Infiltration von Leukozyten im Verlauf des ARDS, scheint ein 
möglicher Beitrag des Kontaktaktiverungssystems zur Lungenschädigung die von FXII 
und KLK induzierte Aktivierung von Neutrophilen zu sein. Eine weitere wichtige 
Erkenntnis war die Beobachtung eines erhöhten Bradykinin (BK) Levels bei ARDS 
Patienten ebenso wie im Tiermodel der Lungenschädigung, mutmaßlich ausgelöst 
durch die erhöhte Aktivität des Kontaktaktivierungungssystems. Zur Schädigung der 
Lunge trägt BK möglicherweise neben seiner proentzündlichen Wirkung auch durch die 
Erhöhung der alveolarkapillären Permeabilität bei, welche eine Zunahme des 
Lungenödems zur Folge hat. Desweiteren konnte der Nachweis von mRNA in 
Leukozyten von ARDS Patienten erbracht werden, eine extrahepatische FXII Synthese 
scheint folglich unter pathologischen Bedingungen eine zusätzliche Rolle zu spielen. 
Von besonderem Interesse für zukünftige therapeutische Forschungsansätze ist der 
hier erbrachte Nachweis eines positiven Effekts von C1 INH Applikation auf die 
Lungenschädigung. Die Verabreichung von C1 INH milderte den entzündlichen 
Prozess im Lungengewebe, reduzierte die Anzahl der inflammatorischen Zellen, 
insbesondere der Neutrophilen und bewirkte eine Reduktion des Lungenödems. 
Desweiteren  zeigte sich ein signifikanter Rückgang der Zytokine Tumornekrose 
Faktor-α (TNF-α) und macrophage inflammatory protein-2 (MIP-2).  
Zusammenfassend weisen die Ergebnisse dieser Studie auf eine Beteiligung der 
Faktoren des Komplementaktivierungssystems in der Pathogenese von ARDS hin. 
Möglicherweise induzieren die untersuchten Proteasen hierbei die Zytokinfreisetzung 
und unterstützen so die Lungengewebsschädigung durch Überstimulation von 
Neutrophilen. Die Gabe von C1 INH zeigte einen protektiven Effekt auf die 
Lungenschädigung und weist auf die antiinflammatorische Kapazität des Serine 
Protease Inhibitors hin. Diese beruht möglicherweise auf der Fähigkeit des C1 INH 
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mittels Blockade von Selektinen die endothelial Leukozyten Adhäsion zu stören und 
somit die Invasion der Entzündungszelle in das Lungengewebe zu hemmen.  Die 
Untersuchung richtet somit ein neues Interesse auf C1 INH als eine zukünftige 
therapeutische Option in der Behandlung von entzündlichen Lungenerkrankungen wie 
ARDS. 
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8.  List of abbreviations 
 
AECC  American European Conference Committee 
ALI  Acute lung injury 
APS  Ammonium persulfate 
α-SMA  α-smooth muscle actin 
Asp  Aspartic acid 
ARDS  Acute respiratory distress syndrome 
AT III  Anti-thrombin III 
BALF  Broncho-alveolar lavage fluid 
BK  Bradykinin 
B1R  Bradykinin-1-receptor 
B2R  Bradykinin-2-receptor 
BSA  Bovine serum albumin 
C1q  First component of the complement system 
C1 INH C1 esterase inhibitor 
CD  Cluster of differentiation 
cDNA  Complementary deoxyribonucleic acid 
CLE  Cardiogenic pulmonary edema 
CTI  Corn trypsin inhibitor 
CXCL1 Chemokine (C-X-C motif) ligand 1 
EDTA  Ethylendinitriol-N,N,N`,N`,-tetraacetic acid 
EGF  Epidermal growth factor 
ELISA  Enzyme linked immunosorbent assay 
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FX  Factor X 
FXI  Factor XI 
FXII  Factor XII 
gC1qR  Complement component C1 subcomponent-binding receptor 
G-CSF  Granulocyte-colony stimulating factor 
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